BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D; ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v50-7. [PMID: 27664261 DOI: 10.1093/annonc/mdw329] [Cited by in Crossref: 372] [Cited by in F6Publishing: 350] [Article Influence: 74.4] [Reference Citation Analysis]
Number Citing Articles
1 Hartfiel S, Häfner M, Perez RL, Rühle A, Trinh T, Debus J, Huber PE, Nicolay NH. Differential response of esophageal cancer cells to particle irradiation. Radiat Oncol 2019;14:119. [PMID: 31286978 DOI: 10.1186/s13014-019-1326-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Lindenmann J, Fediuk M, Fink-Neuboeck N, Porubsky C, Pichler M, Brcic L, Anegg U, Balic M, Dandachi N, Maier A, Smolle M, Smolle J, Smolle-Juettner FM. Hazard Curves for Tumor Recurrence and Tumor-Related Death Following Esophagectomy for Esophageal Cancer. Cancers (Basel) 2020;12:E2066. [PMID: 32726927 DOI: 10.3390/cancers12082066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Mao C, Zeng X, Zhang C, Yang Y, Xiao X, Luan S, Zhang Y, Yuan Y. Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer. Front Cell Dev Biol 2021;9:612451. [PMID: 33644048 DOI: 10.3389/fcell.2021.612451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Krug S, Michl P. Esophageal Cancer: New Insights into a Heterogenous Disease. Digestion 2017;95:253-61. [DOI: 10.1159/000464130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
5 Grillo F, Mastracci L, Saragoni L, Vanoli A, Limarzi F, Gullo I, Ferro J, Paudice M, Parente P, Fassan M. Neoplastic and pre-neoplastic lesions of the oesophagus and gastro-oesophageal junction. Pathologica 2020;112:138-52. [PMID: 33179618 DOI: 10.32074/1591-951X-164] [Reference Citation Analysis]
6 Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J; AME Thoracic Surgery Collaborative Group. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018;36:2796-2803. [PMID: 30089078 DOI: 10.1200/jco.2018.79.1483] [Cited by in Crossref: 142] [Cited by in F6Publishing: 122] [Article Influence: 47.3] [Reference Citation Analysis]
7 Xi M, Xu C, Liao Z, Hofstetter WL, Blum Murphy M, Maru DM, Bhutani MS, Lee JH, Weston B, Komaki R, Lin SH. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 2017;124:318-24. [PMID: 28687396 DOI: 10.1016/j.radonc.2017.06.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
8 Dyhl-Polk A, Vaage-Nilsen M, Schou M, Vistisen KK, Lund CM, Kümler T, Appel JM, Nielsen DL. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer. Acta Oncol 2020;59:475-83. [PMID: 31931649 DOI: 10.1080/0284186X.2019.1711164] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
9 Goense L, Meziani J, van Rossum PS, Wessels FJ, Meijer GJ, Lam MG, van Hillegersberg R, Ruurda JP. Limited additional value of cervical ultrasonography over a negative 18F-FDG PET/CT for diagnosing cervical lymph node metastases in patients with esophageal cancer: a systematic review and meta-analysis. Nuclear Medicine Communications 2018;39:645-51. [DOI: 10.1097/mnm.0000000000000847] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Qu J, Zhao Q, Yang L, Ping Y, Zhang K, Lei Q, Liu F, Zhang Y. Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma. Int Immunopharmacol 2021;96:107616. [PMID: 34162127 DOI: 10.1016/j.intimp.2021.107616] [Reference Citation Analysis]
11 Anderluh F, Toplak M, Velenik V, Oblak I, Ermenc AS, Peressutti AJ, But-Hadzic J, Vidmar MS. Definitive radiochemotherapy in esophageal cancer - a single institution experience. Radiol Oncol 2019;53:480-7. [PMID: 31747382 DOI: 10.2478/raon-2019-0054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Lam KO, Kwong DLW. Chemotherapy for Esophageal Adenocarcinoma. Methods Mol Biol 2018;1756:19-34. [PMID: 29600357 DOI: 10.1007/978-1-4939-7734-5_3] [Reference Citation Analysis]
13 Allum W, Lordick F, Alsina M, Andritsch E, Ba-Ssalamah A, Beishon M, Braga M, Caballero C, Carneiro F, Cassinello F, Dekker JW, Delgado-Bolton R, Haustermans K, Henning G, Hutter B, Lövey J, Netíková IŠ, Obermannová R, Oberst S, Rostoft S, Saarto T, Seufferlein T, Sheth S, Wynter-Blyth V, Costa A, Naredi P. ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. Crit Rev Oncol Hematol 2018;122:179-93. [PMID: 29458786 DOI: 10.1016/j.critrevonc.2017.12.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
14 Sanz Álvarez L, Turienzo Santos E, Rodicio Miravalles JL, Moreno Gijón M, Amoza Pais S, Sanz Navarro S, Rizzo Ramos A. Evidence in follow-up and prognosis of esophagogastric junction cancer. Cir Esp (Engl Ed) 2019;97:465-9. [PMID: 31060735 DOI: 10.1016/j.ciresp.2019.03.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 McMenamin ÚC, Trainor J, Coleman HG, McManus DT, McQuaid S, Bingham V, James J, Salto-Tellez M, Johnston BT, Turkington RC. Sex hormone receptor expression and survival in esophageal adenocarcinoma: a prospective cohort study. Oncotarget 2018;9:35300-12. [PMID: 30450159 DOI: 10.18632/oncotarget.26236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Babic B, Schiffmann LM, Schröder W, Bruns CJ, Fuchs HF. [Evidence in minimally invasive oncological surgery of the esophagus]. Chirurg 2021;92:299-303. [PMID: 33432385 DOI: 10.1007/s00104-020-01337-x] [Reference Citation Analysis]
17 Wang L, Dong G, Xia W, Mao Q, Wang A, Chen B, Ma W, Wu Y, Xu L, Jiang F. Integrative analysis of differential genes and identification of a "2-gene score" associated with survival in esophageal squamous cell carcinoma. Thorac Cancer 2019;10:60-70. [PMID: 30421504 DOI: 10.1111/1759-7714.12902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Modesto A, Carrère N, Guimbaud R, Rives M, Deutsch É, Quéro L, Créhange G. [Definitive or neo-adjuvant chemoradiation in esophageal carcinoma?]. Cancer Radiother 2019;23:716-9. [PMID: 31421997 DOI: 10.1016/j.canrad.2019.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Luijten JCHBM, Vissers PAJ, Lingsma H, van Leeuwen N, Rozema T, Siersema PD, Rosman C, van Laarhoven HWM, Lemmens VEP, Nieuwenhuijzen GAP, Verhoeven RHA. Changes in hospital variation in the probability of receiving treatment with curative intent for esophageal and gastric cancer. Cancer Epidemiol 2021;71:101897. [PMID: 33484974 DOI: 10.1016/j.canep.2021.101897] [Reference Citation Analysis]
20 Adenis A, Castan F, Conroy T. Consolidation chemotherapy after definite concurrent chemoradiation in patients with non-operable esophageal cancer: Is it useful? Radiother Oncol 2018;129:180-1. [PMID: 29331543 DOI: 10.1016/j.radonc.2017.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Whooley J, Alazzawi M, Donlon NE, Bolger JC, Robb WB. PD-1 inhibitors in esophageal cancer: a systematic review of the oncological outcomes associated with PD-1 blockade and the evolving therapeutic paradigm. Dis Esophagus 2021:doab063. [PMID: 34553222 DOI: 10.1093/dote/doab063] [Reference Citation Analysis]
22 Reichenbach ZW, Murray MG, Saxena R, Farkas D, Karassik EG, Klochkova A, Patel K, Tice C, Hall TM, Gang J, Parkman HP, Ward SJ, Tétreault M, Whelan KA. Clinical and translational advances in esophageal squamous cell carcinoma. Elsevier; 2019. pp. 95-135. [DOI: 10.1016/bs.acr.2019.05.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
23 Hou S, Pan Z, Hao X, Hang Q, Ding Y. Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer. Cancers (Basel) 2021;13:5162. [PMID: 34680311 DOI: 10.3390/cancers13205162] [Reference Citation Analysis]
24 Helminen O, Kauppila JH, Kytö V, Gunn J, Lagergren J, Sihvo E. Preoperative esophageal stenting and short-term outcomes of surgery for esophageal cancer in a population-based study from Finland and Sweden. Diseases of the Esophagus 2019;32:doz005. [DOI: 10.1093/dote/doz005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Roy AC, Shapiro J, Burge M, Karapetis CS, Pavlakis N, Segelov E, Chau I, Lordick F, Chen LT, Barbour A, Tebbutt N, Price T. Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther 2020;20:305-24. [PMID: 32202178 DOI: 10.1080/14737140.2020.1746185] [Reference Citation Analysis]
26 Faron M, Cheugoua-Zanetsie AM, Thirion P, Nankivell M, Winter K, Cunningham D, Van der Gaast A, Law S, Langley R, de Vathaire F, Valmasoni M, Mauer M, Roth J, Gebski V, Burmeister BH, Paoletti X, van Sandick J, Fu J, Ducreux M, Blanchard P, Tierney J, Pignon JP, Michiels S; MANATEC-02 collaborative group. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction. Eur J Cancer 2021;157:278-90. [PMID: 34555647 DOI: 10.1016/j.ejca.2021.08.014] [Reference Citation Analysis]
27 Ahmed O, Lee JH, Thompson CC, Faulx A. AGA Clinical Practice Update on the Optimal Management of the Malignant Alimentary Tract Obstruction: Expert Review.Clin Gastroenterol Hepatol. 2021;. [PMID: 33813072 DOI: 10.1016/j.cgh.2021.03.046] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Miyata H, Sugimura K, Kanemura T, Takeoka T, Yamamoto M, Shinno N, Hara H, Omori T, Yamamoto S, Ishihara R, Wada H, Takahashi H, Nishimura J, Matsuda C, Yasui M, Yano M. Clinical Outcome of Additional Esophagectomy After Endoscopic Treatment for Superficial Esophageal Cancer. Ann Surg Oncol 2021. [PMID: 33959832 DOI: 10.1245/s10434-021-09864-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Oweira H, Schmidt J, Mehrabi A, Kulaksiz H, Schneider P, Schöb O, Giryes A, Abdel-Rahman O. Validation of the eighth clinical American Joint Committee on Cancer stage grouping for esophageal cancer. Future Oncol 2018;14:65-75. [PMID: 29235888 DOI: 10.2217/fon-2017-0376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Chiapponi C, Berlth F, Plum PS, Betzler C, Stippel DL, Popp F, Bruns CJ. Oligometastatic Disease in Upper Gastrointestinal Cancer - How to Proceed? Visc Med 2017;33:31-4. [PMID: 28612014 DOI: 10.1159/000455683] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
31 Hamamoto Y, Sakakibara N, Nagashima F, Kitagawa Y, Higashi T. Treatment selection for esophageal cancer: evaluation from a nationwide database. Esophagus 2018;15:109-14. [PMID: 29892936 DOI: 10.1007/s10388-018-0605-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Sardaro A, Ferrari C, Carbonara R, Altini C, Lavelli V, Rubini G. Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives. Cancer Biother Radiopharm 2021;36:123-32. [PMID: 32551915 DOI: 10.1089/cbr.2020.3643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Davis LE, Gupta V, Allen-Ayodabo C, Zhao H, Hallet J, Mahar AL, Ringash J, Doherty M, Kidane B, Darling G, Coburn NG. Patient-reported symptoms following diagnosis in esophagus cancer patients treated with palliative intent. Dis Esophagus 2020;33:doz108. [PMID: 31957801 DOI: 10.1093/dote/doz108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Zhu L, Dong L, Feng M, Yang F, Jiang W, Huang Z, Liu F, Wang L, Wang G, Li Q. Profiles of autophagy-related genes in esophageal adenocarcinoma. BMC Cancer 2020;20:943. [PMID: 32998713 DOI: 10.1186/s12885-020-07416-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Lin YT, Chen Y, Liu TX, Kuang F, Huang P. Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma. Cancer Manag Res 2021;13:8219-30. [PMID: 34754242 DOI: 10.2147/CMAR.S335515] [Reference Citation Analysis]
36 Lopes N, Correia MP, Henrique R, Jerónimo C. Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes. Int J Mol Sci 2020;21:E3522. [PMID: 32429269 DOI: 10.3390/ijms21103522] [Reference Citation Analysis]
37 Martini S, Arcadipane F, Strignano P, Spadi R, Contu V, Fiandra C, Ragona R, Catalano G, Satolli MA, Camandona M, Romagnoli R, Ricardi U, Franco P. Volumetric modulated arc therapy (VMAT) in the treatment of esophageal cancer patients. Med Oncol 2018;35:150. [PMID: 30284647 DOI: 10.1007/s12032-018-1211-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
38 Depypere L, Moons J, Lerut T, De Hertogh G, Peters C, Sagaert X, Coosemans W, Van Veer H, Nafteux P. Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy. Diseases of the Esophagus 2018;31. [DOI: 10.1093/dote/dox117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
39 Kamarajah SK, Phillips AW, Ferri L, Hofstetter WL, Markar SR. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study. Br J Surg 2021;108:403-11. [PMID: 33755097 DOI: 10.1093/bjs/znaa121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 de Vos-Geelen J, Geurts SME, Nieuwenhuijzen GAP, Voncken FEM, Bogers JA, Braam PM, Muijs CT, de Jong MA, Kasperts N, Rozema T, Blom GJ, Bouwense SAW, Valkenburg-van Iersel LBJ, Jeene PM, Hoebers FJP, Tjan-Heijnen VCG. Patterns of recurrence following definitive chemoradiation for patients with proximal esophageal cancer. Eur J Surg Oncol 2021;47:2016-22. [PMID: 33583629 DOI: 10.1016/j.ejso.2021.02.001] [Reference Citation Analysis]
41 Yang J, Liu X, Cao S, Dong X, Rao S, Cai K. Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade. Front Oncol 2020;10:1727. [PMID: 33014854 DOI: 10.3389/fonc.2020.01727] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
42 van de Ven S, Bugter O, Hardillo JA, Bruno MJ, Baatenburg de Jong RJ, Koch AD. Screening for head and neck second primary tumors in patients with esophageal squamous cell cancer: A systematic review and meta-analysis. United European Gastroenterol J 2019;7:1304-11. [PMID: 31839955 DOI: 10.1177/2050640619856459] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
43 Ter Veer E, van Oijen MGH, van Laarhoven HWM. The Use of (Network) Meta-Analysis in Clinical Oncology. Front Oncol 2019;9:822. [PMID: 31508373 DOI: 10.3389/fonc.2019.00822] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
44 Al-Kaabi A, van der Post RS, Huising J, Rosman C, Nagtegaal ID, Siersema PD. Predicting lymph node metastases with endoscopic resection in cT2N0M0 oesophageal cancer: A systematic review and meta-analysis. United European Gastroenterol J 2020;8:35-43. [PMID: 32213055 DOI: 10.1177/2050640619879007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Peerlings J, Paulis L, Mitea C, Bakers F, Berbée M, Wierts R, Vöö S, Wildberger J, Hoffmann A, Lambin P, Mottaghy F. Performing clinical 18F-FDG-PET/MRI of the mediastinum optimising a dedicated, patient-friendly protocol. Nucl Med Commun 2019;40:815-26. [PMID: 31169592 DOI: 10.1097/MNM.0000000000001035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Celik E, Baues C, Claus K, Fogliata A, Scorsetti M, Marnitz S, Cozzi L. Knowledge-based intensity-modulated proton planning for gastroesophageal carcinoma. Acta Oncol 2021;60:285-92. [PMID: 33170066 DOI: 10.1080/0284186X.2020.1845396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Lam KO, Chan WWL, So TH, Kwong DLW. Systemic Therapy for Esophageal Squamous Cell Carcinoma. Methods Mol Biol 2020;2129:321-33. [PMID: 32056188 DOI: 10.1007/978-1-0716-0377-2_24] [Reference Citation Analysis]
48 Huang B, Kechagias A, Tsekrekos A, Lovece A, Hayami M, Rouvelas I. Presentation of gastroesophageal junction adenocarcinoma with synchronous metastases at the small intestine. Could treatment with curative intent be considered? A case report. Int J Surg Case Rep 2021;84:106164. [PMID: 34218020 DOI: 10.1016/j.ijscr.2021.106164] [Reference Citation Analysis]
49 Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Bütof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Löck S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Pöttgen C, Rödel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zöphel K, Zschaeck S, Thorwarth D, Troost EGC; “Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN”. Value of PET imaging for radiation therapy. Nuklearmedizin 2021. [PMID: 34261141 DOI: 10.1055/a-1525-7029] [Reference Citation Analysis]
50 Reinert CP, Sekler J, Gani C, Nikolaou K, la Fougère C, Pfannenberg C, Gatidis S. Impact of PET/CT on management of patients with esophageal cancer - results from a PET/CT registry study. Eur J Radiol 2021;136:109524. [PMID: 33434862 DOI: 10.1016/j.ejrad.2021.109524] [Reference Citation Analysis]
51 van der Kaaij RT, Voncken FEM, van Dieren JM, Snaebjornsson P, Korse CM, Grootscholten C, Aleman BMP, van Sandick JW. Elevated Pretreatment CEA and CA19-9 Levels are Related to Early Treatment Failure in Esophageal Adenocarcinoma. Am J Clin Oncol 2019;42:345-50. [PMID: 30724779 DOI: 10.1097/COC.0000000000000525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Zhang HJ, Chen G, Chen SW, Fu ZW, Zhou HF, Feng ZB, Mo JX, Li CB, Liu J. Overexpression of cyclin-dependent kinase 1 in esophageal squamous cell carcinoma and its clinical significance. FEBS Open Bio 2021;11:3126-41. [PMID: 34586751 DOI: 10.1002/2211-5463.13306] [Reference Citation Analysis]
53 Fatehi Hassanabad A, Chehade R, Breadner D, Raphael J. Esophageal carcinoma: Towards targeted therapies. Cell Oncol (Dordr) 2020;43:195-209. [PMID: 31848929 DOI: 10.1007/s13402-019-00488-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 10.5] [Reference Citation Analysis]
54 Shuai Y, Duan Y, Zhou M, Yue K, Liu D, Fang Y, Wang Y, Wu Y, Zhang Z, Wang X. Development and Validation of a Nomogram based on cell growth-related Biomarkers for Oral Squamous Cell Carcinoma. J Cancer 2021;12:5153-63. [PMID: 34335932 DOI: 10.7150/jca.54475] [Reference Citation Analysis]
55 Al-Kaabi A, van der Post RS, van der Werf LR, Wijnhoven BPL, Rosman C, Hulshof MCCM, van Laarhoven HWM, Verhoeven RHA, Siersema PD. Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study. Acta Oncol 2021;60:497-504. [PMID: 33491513 DOI: 10.1080/0284186X.2020.1870246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Li C, Tan L, Liu X, Wang X, Zhou Z, Chen D, Feng Q, Liang J, Lv J, Wang X, Bi N, Deng L, Wang W, Zhang T, Ni W, Chang X, Han W, Gao L, Wang S, Xiao Z. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis. Thorac Cancer 2021;12:1831-40. [PMID: 33949784 DOI: 10.1111/1759-7714.13971] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Li CC, Chen CY, Chou YH, Huang CJ, Ku HY, Chien CR. Chemotherapy alone versus definitive concurrent chemoradiotherapy for cT4b esophageal squamous cell carcinoma: a population-based study. BMC Gastroenterol 2021;21:153. [PMID: 33827451 DOI: 10.1186/s12876-021-01742-4] [Reference Citation Analysis]
58 Thomas M, Defraene G, Lambrecht M, Deng W, Moons J, Nafteux P, Lin SH, Haustermans K. NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. Radiotherapy and Oncology 2019;141:33-40. [DOI: 10.1016/j.radonc.2019.09.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
59 Smyth E, Knödler M, Giraut A, Mauer M, Nilsson M, Van Grieken N, Wagner AD, Moehler M, Lordick F. VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study. Front Oncol 2019;9:1320. [PMID: 32083013 DOI: 10.3389/fonc.2019.01320] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
60 Aggelis V, Cunningham D, Lordick F, Smyth EC. Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future. Ann Oncol 2018;29:1377-85. [PMID: 29771279 DOI: 10.1093/annonc/mdy183] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
61 Zhao Z, Zhang Y, Wang X, Geng X, Zhu L, Li M. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy. Cancer Med 2020;9:5881-8. [PMID: 32627960 DOI: 10.1002/cam4.3273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
62 Smyth EC, Gambardella V, Cervantes A, Fleitas T. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol 2021;32:590-9. [PMID: 33609722 DOI: 10.1016/j.annonc.2021.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
63 St-Amour P, Winiker M, Sempoux C, Fasquelle F, Demartines N, Schäfer M, Mantziari S. The "Real R0": A Resection Margin Smaller Than 0.1 cm is Associated with a Poor Prognosis After Oncologic Esophagectomy. Ann Surg Oncol 2021. [PMID: 34041624 DOI: 10.1245/s10434-021-10121-y] [Reference Citation Analysis]
64 Xi M, Liao Z, Deng W, Komaki R, Ho L, Lin SH. Recursive Partitioning Analysis Identifies Pretreatment Risk Groups for the Utility of Induction Chemotherapy Before Definitive Chemoradiation Therapy in Esophageal Cancer. Int J Radiat Oncol Biol Phys 2017;99:407-16. [PMID: 28871991 DOI: 10.1016/j.ijrobp.2017.05.050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
65 Triantafyllou T, Wijnhoven BPL. Current status of esophageal cancer treatment. Chin J Cancer Res 2020;32:271-86. [PMID: 32694894 DOI: 10.21147/j.issn.1000-9604.2020.03.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Qiu X, Li J, Zhou H, Zhang M, Jiang C, Shen Z, Zhu X, Li A, Che Y, Wu T, Wang Z. Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma. Medicine (Baltimore) 2020;99:e18732. [PMID: 31977864 DOI: 10.1097/MD.0000000000018732] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg 2018;268:289-95. [PMID: 28628563 DOI: 10.1097/SLA.0000000000002352] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 6.5] [Reference Citation Analysis]
68 Helminen O, Sihvo E, Gunn J, Sipilä JOT, Rautava P, Kytö V. Trends and results of oesophageal cancer surgery in Finland between 2004 and 2014. European Journal of Cardio-Thoracic Surgery 2020;57:107-13. [DOI: 10.1093/ejcts/ezz189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
69 Mantziari S, Gronnier C, Renaud F, Duhamel A, Théreaux J, Brigand C, Carrère N, Lefevre JH, Pasquer A, Demartines N, Collet D, Meunier B, Mariette C; FREGAT working group – FRENCH – AFC. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study. Ann Surg 2017;266:805-13. [PMID: 28742698 DOI: 10.1097/SLA.0000000000002402] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
70 Puhr HC, Wolf P, Berghoff AS, Schoppmann SF, Preusser M, Ilhan-Mutlu A. Elevated Free Thyroxine Levels Are Associated with Poorer Overall Survival in Patients with Gastroesophageal Cancer: A Retrospective Single Center Analysis. Horm Cancer 2020;11:42-51. [PMID: 31884578 DOI: 10.1007/s12672-019-00374-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Nakanoko T, Morita M, Nakashima Y, Ota M, Ikebe M, Yamamoto M, Booka E, Takeuchi H, Kitagawa Y, Matsubara H, Doki Y, Toh Y. Nationwide survey of the follow-up practices for patients with esophageal carcinoma after radical treatment: historical changes and future perspectives in Japan. Esophagus 2021. [PMID: 34383154 DOI: 10.1007/s10388-021-00869-3] [Reference Citation Analysis]
72 Goense L, van Rossum PSN, Xi M, Maru DM, Carter BW, Meijer GJ, Ho L, van Hillegersberg R, Hofstetter WL, Lin SH. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma. Ann Surg Oncol 2018;25:1598-607. [PMID: 29569125 DOI: 10.1245/s10434-018-6435-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
73 van Kleef JJ, van den Boorn HG, Verhoeven RHA, Vanschoenbeek K, Abu-Hanna A, Zwinderman AH, Sprangers MAG, van Oijen MGH, De Schutter H, van Laarhoven HWM. External Validation of the Dutch SOURCE Survival Prediction Model in Belgian Metastatic Oesophageal and Gastric Cancer Patients. Cancers (Basel) 2020;12:E834. [PMID: 32244310 DOI: 10.3390/cancers12040834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
74 Inderson A, Slingerland M, Farina Sarasqueta A, de Steur WO, Boonstra JJ. EUS-guided radiofrequency ablation for a left adrenal oligometastasis of an esophageal adenocarcinoma. VideoGIE 2018;3:159-61. [PMID: 29916497 DOI: 10.1016/j.vgie.2018.03.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
75 Simoni N, Pavarana M, Micera R, Weindelmayer J, Mengardo V, Rossi G, Cenzi D, Tomezzoli A, Del Bianco P, Giacopuzzi S, De Manzoni G, Mazzarotto R. Long-Term Outcomes of Induction Chemotherapy Followed by Chemo-Radiotherapy as Intensive Neoadjuvant Protocol in Patients with Esophageal Cancer. Cancers (Basel) 2020;12:E3614. [PMID: 33287147 DOI: 10.3390/cancers12123614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Valmasoni M, Pierobon ES, Zanchettin G, Briscolini D, Moletta L, Ruol A, Salvador R, Merigliano S. Cervical Esophageal Cancer Treatment Strategies: A Cohort Study Appraising the Debated Role of Surgery. Ann Surg Oncol. 2018;25:2747-2755. [PMID: 29987601 DOI: 10.1245/s10434-018-6648-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
77 Ren W, Sha H, Yan J, Wu P, Yang J, Li R, Zhang H, Yu L, Qian H, Liu B. Enhancement of radiotherapeutic efficacy for esophageal cancer by paclitaxel-loaded red blood cell membrane nanoparticles modified by the recombinant protein anti-EGFR-iRGD. J Biomater Appl 2018;33:707-24. [PMID: 30388386 DOI: 10.1177/0885328218809019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
78 van de Water LF, van den Boorn HG, Hoxha F, Henselmans I, Calff MM, Sprangers MAG, Abu-Hanna A, Smets EMA, van Laarhoven HWM. Informing Patients With Esophagogastric Cancer About Treatment Outcomes by Using a Web-Based Tool and Training: Development and Evaluation Study. J Med Internet Res 2021;23:e27824. [PMID: 34448703 DOI: 10.2196/27824] [Reference Citation Analysis]
79 Omari J, Heinze C, Wilck A, Hass P, Seidensticker M, Damm R, Fischbach K, Ricke J, Pech M, Powerski M. Image-guided interstitial high-dose-rate brachytherapy in the treatment of metastatic esophageal squamous cell carcinoma. J Contemp Brachytherapy 2018;10:439-45. [PMID: 30479621 DOI: 10.5114/jcb.2018.79230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
80 Kuo YH, Fang HY, Lin YS, Lein MY, Yang CY, Ho SC, Li CC, Chien CR. Effectiveness of image-guided radiotherapy for locally advanced esophageal squamous cell carcinoma patients treated with definitive concurrent chemoradiotherapy. Thorac Cancer 2020;11:113-9. [PMID: 31742897 DOI: 10.1111/1759-7714.13244] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
81 Ma K, Yang Y, Wang S, Yang X, Lu T, Xi J, Jiang W, Zhan C, Zhu Y, Wang Q. Stage selection for neoadjuvant radiotherapy in non-cervical esophageal cancer: A propensity score-matched study based on the SEER database. Thorac Cancer 2018;9:1111-20. [PMID: 29961955 DOI: 10.1111/1759-7714.12794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Huang YC, Kung PT, Ho SY, Tyan YS, Chiu LT, Tsai WC. Effect of multidisciplinary team care on survival of oesophageal cancer patients: a retrospective nationwide cohort study. Sci Rep 2021;11:13243. [PMID: 34168186 DOI: 10.1038/s41598-021-92618-w] [Reference Citation Analysis]
83 Groulx S, Limburg H, Doull M, Klarenbach S, Singh H, Wilson BJ, Thombs B; Canadian Task Force on Preventive Health Care. Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease. CMAJ 2020;192:E768-77. [PMID: 32631908 DOI: 10.1503/cmaj.190814] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Lampis A, Ratti M, Ghidini M, Mirchev MB, Okuducu AF, Valeri N, Hahne JC. Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review). Int J Mol Med 2021;47:97. [PMID: 33846775 DOI: 10.3892/ijmm.2021.4930] [Reference Citation Analysis]
85 Koemans WJ, Larue RTHM, Kloft M, Ruisch JE, Compter I, Riedl RG, Heij LR, van Elmpt W, Berbée M, Buijsen J, Lambin P, Sosef MN, Grabsch HI. Lymph node response to chemoradiotherapy in oesophageal cancer patients: relationship with radiotherapy fields. Esophagus 2021;18:100-10. [PMID: 32889674 DOI: 10.1007/s10388-020-00777-y] [Reference Citation Analysis]
86 Alvarez-Manceñido F, Jimenez-Fonseca P, Carmona-Bayonas A, Arrazubi V, Hernandez R, Cano JM, Custodio A, Pericay Pijaume C, Aguado G, Martínez Lago N, Sánchez Cánovas M, Cacho Lavin D, Visa L, Martinez-Torron A, Arias-Martinez A, López F, Limón ML, Vidal Tocino R, Fernández Montes A, Alsina M, Pimentel P, Reguera P, Martín Carnicero A, Ramchandani A, Granja M, Azkarate A, Martín Richard M, Serra O, Hernández Pérez C, Hurtado A, Gil-Negrete A, Sauri T, Morales Del Burgo P, Gallego J. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Gastric Cancer 2021;24:926-36. [PMID: 33651195 DOI: 10.1007/s10120-021-01169-6] [Reference Citation Analysis]
87 Depypere LP, Vervloet G, Lerut T, Moons J, De Hertogh G, Sagaert X, Coosemans W, Van Veer H, Nafteux PR. ypT0N+: the unusual patient with pathological complete tumor response but with residual lymph node disease after neoadjuvant chemoradiation for esophageal cancer, what's up? J Thorac Dis 2018;10:2771-8. [PMID: 29997939 DOI: 10.21037/jtd.2018.04.136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
88 Hammoudi N, Hennequin C, Vercellino L, Costantini A, Valverde A, Cattan P, Quéro L. Early metabolic response to chemoradiotherapy by interim FDG PET/CT is associated with better overall survival and histological response in esophageal cancers. Digestive and Liver Disease 2019;51:887-93. [DOI: 10.1016/j.dld.2018.12.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Al-Kaabi A, Schoon EJ, Deprez PH, Seewald S, Groth S, Giovannini M, Braden B, Berr F, Lemmers A, Hoare J, Bhandari P, van der Post RS, Verhoeven RHA, Siersema PD. Salvage endoscopic resection after definitive chemoradiotherapy for esophageal cancer: a Western experience. Gastrointest Endosc 2021;93:888-898.e1. [PMID: 32763242 DOI: 10.1016/j.gie.2020.07.062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Sihvo E, Helminen O, Gunn J, Sipilä JO, Rautava P, Kytö V. Long-term outcomes following minimally invasive and open esophagectomy in Finland: A population-based study. European Journal of Surgical Oncology 2019;45:1099-104. [DOI: 10.1016/j.ejso.2018.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
91 Sato H, Terai S, Shimamura Y, Tanaka S, Shiwaku H, Minami H, Sato C, Ogawa R, Yokomichi H, Inoue H. Achalasia and esophageal cancer: a large database analysis in Japan. J Gastroenterol 2021;56:360-70. [PMID: 33538893 DOI: 10.1007/s00535-021-01763-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Kiyozumi Y, Yoshida N, Ishimoto T, Yagi T, Koga Y, Uchihara T, Sawayama H, Hiyoshi Y, Iwatsuki M, Baba Y, Miyamoto Y, Watanabe M, Matsuyama T, Oya N, Baba H. Prognostic Factors of Salvage Esophagectomy for Residual or Recurrent Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy. World J Surg 2018;42:2887-93. [PMID: 29423738 DOI: 10.1007/s00268-018-4536-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
93 Smyth EC, Cafferkey C, Loehr A, Waddell T, Begum R, Peckitt C, Harding TC, Nguyen M, Okines AF, Raponi M, Rao S, Watkins D, Starling N, Middleton GW, Wadsley J, Mansoor W, Crosby T, Wotherspoon A, Chau I, Cunningham D. Genomic loss of heterozygosity and survival in the REAL3 trial. Oncotarget 2018;9:36654-65. [PMID: 30613349 DOI: 10.18632/oncotarget.26336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
94 Adenis A, Bennouna J, Etienne P, Bogart E, Francois E, Galais M, Ben Abdelghani M, Michel P, Metges J, Dahan L, Conroy T, Ghiringhelli F, Drouillard A, El Hajbi F, Samalin E, Hiret S, Delaine-clisant S, Mariette C, Penel N, Piessen G, Le Deley M. Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS). European Journal of Cancer 2019;111:12-20. [DOI: 10.1016/j.ejca.2019.01.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
95 Salta S, Macedo-Silva C, Miranda-Gonçalves V, Lopes N, Gigliano D, Guimarães R, Farinha M, Sousa O, Henrique R, Jerónimo C. A DNA methylation-based test for esophageal cancer detection. Biomark Res 2020;8:68. [PMID: 33292587 DOI: 10.1186/s40364-020-00248-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Dai KY, Yu YC, Leu YS, Chi CW, Chan ML, Tsai CH, Lin HC, Huang WC, Chen YJ. Neoadjuvant Chemoradiotherapy and Larynx-Preserving Surgery for Cervical Esophageal Cancer. J Clin Med 2020;9:E387. [PMID: 32024132 DOI: 10.3390/jcm9020387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Lordick F. Treatment of oesophageal cancer - Stressing the patient perspective. Eur J Cancer 2017;84:360-2. [PMID: 28942866 DOI: 10.1016/j.ejca.2017.08.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Dijksterhuis WPM, Verhoeven RHA, Meijer SL, Slingerland M, Haj Mohammad N, de Vos-Geelen J, Beerepoot LV, van Voorthuizen T, Creemers GJ, van Oijen MGH, van Laarhoven HWM. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. Gastric Cancer 2020;23:579-90. [PMID: 31927675 DOI: 10.1007/s10120-020-01039-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
99 Furuta M, Yokota T, Tsushima T, Todaka A, Machida N, Hamauchi S, Yamazaki K, Fukutomi A, Kawai S, Kawabata T, Onozawa Y, Yasui H. Comparison of enteral nutrition with total parenteral nutrition for patients with locally advanced unresectable esophageal cancer harboring dysphagia in definitive chemoradiotherapy. Jpn J Clin Oncol 2019;49:910-8. [PMID: 31219161 DOI: 10.1093/jjco/hyz089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
100 Zhao XH, Wang D, Wang F, Zhu SC. Comparison of the effect of postoperative radiotherapy with surgery alone for esophagus squamous cell carcinoma patients: A meta-analysis. Medicine (Baltimore) 2018;97:e13168. [PMID: 30461614 DOI: 10.1097/MD.0000000000013168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
101 Depypere LP, Moons J, Mariette C, D’journo XB, Thomas PA, Hölscher AH, Bollschweiler E, van Berge-henegouwen MI, Van Lanschot JJB, Lerut TEMR, Nafteux PR. Impact of Extracapsular Lymph Node Involvement After Neoadjuvant Chemoradiation Therapy Followed by Surgery in Carcinoma of the Esophagus: A Multicenter Study. Annals of Surgery 2018;268:1000-7. [DOI: 10.1097/sla.0000000000002425] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
102 Dijksterhuis WPM, Verhoeven RHA, Slingerland M, Haj Mohammad N, de Vos-Geelen J, Beerepoot LV, van Voorthuizen T, Creemers GJ, van Oijen MGH, van Laarhoven HWM. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study. Int J Cancer. 2020;146:1889-1901. [PMID: 31340065 DOI: 10.1002/ijc.32580] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
103 Shoji Y, Takeuchi H, Fukuda K, Nakamura R, Wada N, Kawakubo H, Kitagawa Y. Air Bubble Sign: A New Screening Method for Anastomotic Leakage After Esophagectomy for Esophageal Cancer. Ann Surg Oncol 2018;25:1061-8. [PMID: 29318416 DOI: 10.1245/s10434-017-6327-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
104 Fokter Dovnik N, Smyth EC. Changes in the therapeutic landscape of oesophago-gastric cancers. Curr Opin Oncol 2021;33:362-7. [PMID: 33720069 DOI: 10.1097/CCO.0000000000000728] [Reference Citation Analysis]
105 Fornaro L, Vasile E, Aprile G, Goetze TO, Vivaldi C, Falcone A, Al-Batran SE. Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions. Cancer Treat Rev 2018;69:90-100. [PMID: 29957366 DOI: 10.1016/j.ctrv.2018.06.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
106 Kroese TE, Dijksterhuis WPM, van Rossum PSN, Verhoeven RHA, Mook S, Haj Mohammad N, Hulshof MCCM, van Berge Henegouwen MI, van Oijen MGH, Ruurda JP, van Laarhoven HWM, van Hillegersberg R. Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Ann Thorac Surg 2021:S0003-4975(21)00306-4. [PMID: 33610543 DOI: 10.1016/j.athoracsur.2021.01.061] [Reference Citation Analysis]
107 Erichsen SB, Slater J, Kiil BJ, Petersen TI, Katballe N, Nielsen MB, Pikelis A, Nordsmark M, Kjaer D. Oncological results and morbidity following intended curative resection and free jejunal graft reconstruction of cervical esophageal cancer: a retrospective Danish consecutive cohort study. Dis Esophagus 2021:doab048. [PMID: 34286828 DOI: 10.1093/dote/doab048] [Reference Citation Analysis]
108 Vivaldi C, Catanese S, Massa V, Pecora I, Salani F, Santi S, Lencioni M, Vasile E, Falcone A, Fornaro L. Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist? Int J Mol Sci 2020;21:E1658. [PMID: 32121290 DOI: 10.3390/ijms21051658] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
109 Goense L, Merrell KW, Arnett AL, Hallemeier CL, Meijer GJ, Ruurda JP, Hofstetter WL, van Hillegersberg R, Lin SH. Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer. The Annals of Thoracic Surgery 2018;106:1541-7. [DOI: 10.1016/j.athoracsur.2018.05.055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
110 Borgstein ABJ, Brunner S, Hayami M, Moons J, Fuchs H, Eshuis WJ, Gisbertz SS, Bruns CJ, Nafteux P, Nilsson M, Schröder W, van Berge Henegouwen MI. Safety of Esophageal Cancer Surgery During the First Wave of the COVID-19 Pandemic in Europe: A Multicenter Study. Ann Surg Oncol 2021;28:4805-13. [PMID: 33830357 DOI: 10.1245/s10434-021-09886-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
111 Elsherif SB, Andreou S, Virarkar M, Soule E, Gopireddy DR, Bhosale PR, Lall C. Role of precision imaging in esophageal cancer.J Thorac Dis. 2020;12:5159-5176. [PMID: 33145093 DOI: 10.21037/jtd.2019.08.15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
112 Davidson M, Chau I. Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches. Expert Rev Anticancer Ther 2018;18:327-38. [PMID: 29431018 DOI: 10.1080/14737140.2018.1438271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
113 Zeng ZM, Xu P, Zhou S, Du HY, Jiang XL, Cai J, Huang L, Liu AW. Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleST-2, in thoracic cancer chest radiation. J Clin Lab Anal 2020;34:e23150. [PMID: 31923333 DOI: 10.1002/jcla.23150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
114 Depypere L, De Hertogh G, Moons J, Provoost AL, Lerut T, Sagaert X, Coosemans W, Van Veer H, Nafteux P. Importance of Lymph Node Response After Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma. Ann Thorac Surg 2020:S0003-4975(20)32144-5. [PMID: 33352178 DOI: 10.1016/j.athoracsur.2020.09.074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Janser FA, Adams O, Bütler V, Schläfli AM, Dislich B, Seiler CA, Kröll D, Langer R, Tschan MP. Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells. Int J Mol Sci 2018;19:E3069. [PMID: 30297650 DOI: 10.3390/ijms19103069] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
116 Helminen O, Mrena J, Sihvo E. Benchmark values for transthoracic esophagectomy are not set as the defined "best possible"-a validation study. J Thorac Dis 2018;10:4085-93. [PMID: 30174852 DOI: 10.21037/jtd.2018.06.86] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
117 Fujiwara Y, Fukuda S, Tsujie M, Kitani K, Yukawa M, Inoue M, Watanabe Y, Higashida M, Kubota H, Okada T, Tsuruta A, Ueno T. Clinical significance of preoperative chemoradiotherapy for advanced esophageal cancer, evaluated by propensity score matching and weighting of inverse probability of treatment. Mol Clin Oncol 2019;10:575-82. [PMID: 31086666 DOI: 10.3892/mco.2019.1843] [Reference Citation Analysis]
118 Miyata H, Sugimura K, Motoori M, Omori T, Yamamoto K, Yanagimoto Y, Shinno N, Yasui M, Takahashi H, Wada H, Ohue M, Yano M. Clinical features of metastasis from superficial squamous cell carcinoma of the thoracic esophagus. Surgery 2019;166:1033-40. [PMID: 31493901 DOI: 10.1016/j.surg.2019.07.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
119 Yamamoto S, Kato K. Immuno-oncology for esophageal cancer. Future Oncol 2020;16:2673-81. [PMID: 32777942 DOI: 10.2217/fon-2020-0545] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
120 Hempel D, Wieland T, Solfrank B, Grossmann V, Steinhard J, Frick A, Hempel L, Eberl T, Gaumann A. Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification. Oncologist 2020;25:e881-6. [PMID: 32323889 DOI: 10.1634/theoncologist.2019-0641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
121 Lin D, Liu G, Jiang D, Yu Y, Wang H, Shi H, Tan L. The role of primary tumor SUVmax in the diagnosis of invasion depth: a step toward clinical T2N0 esophageal cancer. Ann Transl Med 2021;9:112. [PMID: 33569414 DOI: 10.21037/atm-20-4430] [Reference Citation Analysis]
122 Neureiter D, Mayr C, Winkelmann P, Neumayer B, Klieser E, Wagner A, Hufnagl C, Emmanuel K, Holzinger J, Koch O, Kiesslich T, Varga M. Expression of the microRNA-200 Family, microRNA-205, and Markers of Epithelial-Mesenchymal Transition as Predictors for Endoscopic Submucosal Dissection over Esophagectomy in Esophageal Adenocarcinoma: A Single-Center Experience. Cells 2020;9:E486. [PMID: 32093260 DOI: 10.3390/cells9020486] [Reference Citation Analysis]
123 Hironaka S, Komori A, Machida R, Ito Y, Takeuchi H, Ogawa G, Kato K, Onozawa M, Minashi K, Yano T, Nakamura K, Tsushima T, Hara H, Nozaki I, Ura T, Chin K, Fukuda H, Kitagawa Y. The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909. Esophagus 2020;17:417-24. [PMID: 32342253 DOI: 10.1007/s10388-020-00741-w] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
124 Bjerring OS, Hess S, Petersen H, Fristrup CW, Lundell L, Mortensen MB. Value of regular endosonography and [18F]fluorodeoxyglucose PET-CT after surgery for gastro-oesophageal junction, stomach or pancreatic cancer. BJS Open 2021;5:zraa028. [PMID: 33688946 DOI: 10.1093/bjsopen/zraa028] [Reference Citation Analysis]
125 van Rossum PSN, Mohammad NH, Vleggaar FP, van Hillegersberg R. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nat Rev Gastroenterol Hepatol. 2018;15:235-249. [PMID: 29235549 DOI: 10.1038/nrgastro.2017.162] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
126 Borg D, Larsson AH, Hedner C, Nodin B, Johnsson A, Jirström K. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma. J Transl Med 2018;16:290. [PMID: 30355278 DOI: 10.1186/s12967-018-1668-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
127 De Pasqual CA, Weindelmayer J, Laiti S, La Mendola R, Bencivenga M, Alberti L, Giacopuzzi S, de Manzoni G. Perianastomotic drainage in Ivor-Lewis esophagectomy, does habit affect utility? An 11-year single-center experience. Updates Surg 2020;72:47-53. [DOI: 10.1007/s13304-019-00674-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
128 Tsukada Y, Higashi T, Shimada H, Kikuchi Y, Terahara A. The use of neoadjuvant therapy for resectable locally advanced thoracic esophageal squamous cell carcinoma in an analysis of 5016 patients from 305 designated cancer care hospitals in Japan. Int J Clin Oncol 2018;23:81-91. [PMID: 28795280 DOI: 10.1007/s10147-017-1178-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
129 Hou TC, Dai KY, Wu MC, Hua KL, Tai HC, Huang WC, Chen YJ. Bio-physic constraint model using spatial registration of delta 18F-fluorodeoxyglucose positron emission tomography/computed tomography images for predicting radiation pneumonitis in esophageal squamous cell carcinoma patients receiving neoadjuvant chemoradiation. Onco Targets Ther 2019;12:6439-51. [PMID: 31496743 DOI: 10.2147/OTT.S205803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
130 Sisic L, Blank S, Nienhüser H, Haag GM, Jäger D, Bruckner T, Ott K, Schmidt T, Ulrich A. The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma. Surgical Oncology 2020;33:177-88. [DOI: 10.1016/j.suronc.2017.06.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
131 Lorenzen S, Biederstädt A, Ronellenfitsch U, Reißfelder C, Mönig S, Wenz F, Pauligk C, Walker M, Al-Batran SE, Haller B, Hofheinz RD. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer 2020;20:886. [PMID: 32933498 DOI: 10.1186/s12885-020-07388-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
132 Degisors S, Pasquer A, Renaud F, Béhal H, Hec F, Gandon A, Vanderbeken M, Caranhac G, Duhamel A, Piessen G, Mariette C; FREGAT working group. Are Thoracotomy and/or Intrathoracic Anastomosis Still Predictors of Postoperative Mortality After Esophageal Cancer Surgery?: A Nationwide Study. Ann Surg 2017;266:854-62. [PMID: 28742697 DOI: 10.1097/SLA.0000000000002401] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
133 Högner A, Thuss-Patience P. Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma. Pharmaceuticals (Basel) 2021;14:151. [PMID: 33673374 DOI: 10.3390/ph14020151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
134 Boustani J, Rivin Del Campo E, Blanc J, Peiffert D, Benezery K, Pereira R, Rio E, Le Prisé E, Créhange G, Huguet F. Quality Assurance of Dose-Escalated Radiation Therapy in a Randomized Trial for Locally Advanced Oesophageal cancer. Int J Radiat Oncol Biol Phys 2019;105:329-37. [PMID: 31299242 DOI: 10.1016/j.ijrobp.2019.06.2542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
135 Sah BR, Owczarczyk K, Siddique M, Cook GJR, Goh V. Radiomics in esophageal and gastric cancer. Abdom Radiol (NY) 2019;44:2048-58. [PMID: 30116873 DOI: 10.1007/s00261-018-1724-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
136 Nicholas O, Prosser S, Mortensen HR, Radhakrishna G, Hawkins MA, Gwynne SH. The Promise of Proton Beam Therapy for Oesophageal Cancer: A Systematic Review of Dosimetric and Clinical Outcomes. Clin Oncol (R Coll Radiol) 2021;33:e339-58. [PMID: 33931290 DOI: 10.1016/j.clon.2021.04.003] [Reference Citation Analysis]
137 Chaddha U, Hogarth DK, Murgu S. Perspective on airway stenting in inoperable patients with tracheoesophageal fistula after curative-intent treatment for esophageal cancer. J Thorac Dis 2019;11:2165-74. [PMID: 31285911 DOI: 10.21037/jtd.2018.12.128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Li F, Ding N, Zhao Y, Yuan L, Mao Y. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis. Int J Surg. 2018;60:88-100. [PMID: 30389537 DOI: 10.1016/j.ijsu.2018.10.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
139 Onitilo AA, Stankowski-Drengler TJ, Shiyanbola O, Engel J, Tanimu S, Fagbemi SO, Li YH. Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC). Clin Med Res 2021;19:64-71. [PMID: 33789952 DOI: 10.3121/cmr.2021.1573] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
140 Borggreve AS, Kingma BF, Domrachev SA, Koshkin MA, Ruurda JP, Hillegersberg R, Takeda FR, Goense L. Surgical treatment of esophageal cancer in the era of multimodality management. Ann N Y Acad Sci 2018;1434:192-209. [DOI: 10.1111/nyas.13677] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
141 Adhia A, Feinglass J, Schlick CJ, Odell D. Adherence to quality measures improves survival in esophageal cancer in a retrospective cohort study of the national cancer database from 2004 to 2016. J Thorac Dis 2020;12:5446-59. [PMID: 33209378 DOI: 10.21037/jtd-20-1347] [Reference Citation Analysis]
142 Lin CH, Hung TM, Chang YC, Hsieh CH, Shih MC, Huang SM, Yang CK, Chang CF, Chan SC, Yap WK. Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy. Cancers (Basel) 2020;12:E607. [PMID: 32155748 DOI: 10.3390/cancers12030607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
143 Sawyer WP, Luo X, Welch AM, Bolton NM, Brown R, Bolton JS. 15-Year Experience with Multimodality Therapy Including Esophagectomy for Elderly Patients with Locoregional Esophageal Cancer. J Am Coll Surg 2021;232:580-8. [PMID: 33549634 DOI: 10.1016/j.jamcollsurg.2020.11.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
144 Saito Y, Kawakubo H, Takami H, Aoyama J, Mayanagi S, Irino T, Fukuda K, Suda K, Nakamura R, Wada N, Kitagawa Y. Thyroid and Parathyroid Functions After Pharyngo-Laryngo-Esophagectomy for Cervical Esophageal Cancer. Ann Surg Oncol 2019;26:3711-7. [DOI: 10.1245/s10434-019-07476-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Fountoulakis A, Souglakos J, Vini L, Douridas GN, Koumarianou A, Kountourakis P, Agalianos C, Alexandrou A, Dervenis C, Gourtsoyianni S, Gouvas N, Kalogeridi M, Levidou G, Liakakos T, Sgouros J, Sgouros SN, Triantopoulou C, Xynos E. Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer. Updates Surg 2019;71:599-624. [DOI: 10.1007/s13304-019-00696-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
146 Storz L, Walther P, Chemnitzer O, Lyros O, Niebisch S, Mehdorn M, Jansen-Winkeln B, Moulla Y, Büch T, Gockel I, Thieme R. Nrf2/Keap1-Pathway Activation and Reduced Susceptibility to Chemotherapy Treatment by Acidification in Esophageal Adenocarcinoma Cells. Cancers (Basel) 2021;13:2806. [PMID: 34199909 DOI: 10.3390/cancers13112806] [Reference Citation Analysis]
147 Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390:2383-2396. [PMID: 28648400 DOI: 10.1016/s0140-6736(17)31462-9] [Cited by in Crossref: 323] [Cited by in F6Publishing: 207] [Article Influence: 80.8] [Reference Citation Analysis]
148 Davidson M, Cafferkey C, Goode EF, Kouvelakis K, Hughes D, Reguera P, Kalaitzaki E, Peckitt C, Rao S, Watkins D, Chau I, Cunningham D, Starling N. Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. Clin Colorectal Cancer. 2018;17:223-230. [PMID: 29980492 DOI: 10.1016/j.clcc.2018.05.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
149 Steber C, Hughes RT, McTyre ER, Soike M, Farris M, Levine BJ, Pasche B, Levine E, Blackstock AW. Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer. Cureus 2021;13:e12574. [PMID: 33575139 DOI: 10.7759/cureus.12574] [Reference Citation Analysis]
150 Bolidong D, Domoto T, Uehara M, Sabit H, Okumura T, Endo Y, Nakada M, Ninomiya I, Miyashita T, Wong RW, Minamoto T. Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma. Sci Rep 2020;10:11807. [PMID: 32678196 DOI: 10.1038/s41598-020-68713-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
151 Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, Sun JM, Cho BC, Özgüroğlu M, Kojima T, Kostorov V, Hierro C, Zhu Y, McLean LA, Shah S, Doi T. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol 2019;15:1057-66. [PMID: 30735435 DOI: 10.2217/fon-2018-0609] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 20.0] [Reference Citation Analysis]
152 van Putten M, de Vos-Geelen J, Nieuwenhuijzen GAP, Siersema PD, Lemmens VEPP, Rosman C, van der Sangen MJC, Verhoeven RHA. Long-term survival improvement in oesophageal cancer in the Netherlands. Eur J Cancer. 2018;94:138-147. [PMID: 29571082 DOI: 10.1016/j.ejca.2018.02.025] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
153 Adenis A, Piessen G, Azria D. Definitive chemoradiation for resectable carcinoma of the cervical esophagus: do we need more evidence? Ann Transl Med 2017;5:503. [PMID: 29299464 DOI: 10.21037/atm.2017.10.27] [Reference Citation Analysis]
154 Peng C, Cohen DJ. Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma. Expert Opin Pharmacother 2021;22:93-107. [PMID: 33034212 DOI: 10.1080/14656566.2020.1813278] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
155 van Velzen MJM, Pape M, Dijksterhuis WPM, Slingerland M, van Voorthuizen T, Beerepoot LV, Creemers GJ, Derks S, Mohammad NH, Verhoeven RHA, van Laarhoven HWM. The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer. Eur J Cancer 2021;156:60-9. [PMID: 34425405 DOI: 10.1016/j.ejca.2021.07.026] [Reference Citation Analysis]
156 Takeuchi H, Kitagawa Y. Sentinel node navigation surgery in esophageal cancer. Ann Gastroenterol Surg 2019;3:7-13. [PMID: 30697605 DOI: 10.1002/ags3.12206] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
157 Laxague F, Schlottmann F. Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy? World J Clin Oncol 2021; 12(7): 557-564 [PMID: 34367928 DOI: 10.5306/wjco.v12.i7.557] [Reference Citation Analysis]
158 Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof MCCM, Krishnadath KK, Lagarde SM, Nieuwenhuijzen GAP, Oostenbrug LE, Siersema PD, Schoon EJ, Sosef MN, Steyerberg EW, van Lanschot JJB; SANO study group. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol 2018;19:965-74. [PMID: 29861116 DOI: 10.1016/S1470-2045(18)30201-8] [Cited by in Crossref: 77] [Cited by in F6Publishing: 48] [Article Influence: 25.7] [Reference Citation Analysis]
159 Li C, Tan L, Liu X, Wang X, Zhou Z, Chen D, Feng Q, Liang J, Lv J, Wang X, Bi N, Deng L, Wang W, Zhang T, Ni W, Chang X, Han W, Xiao Z. Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. Front Oncol 2021;11:618776. [PMID: 34235073 DOI: 10.3389/fonc.2021.618776] [Reference Citation Analysis]
160 Mayanagi S, Irino T, Kawakubo H, Kitagawa Y. Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer. Ann Gastroenterol Surg 2019;3:269-75. [PMID: 31131355 DOI: 10.1002/ags3.12243] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
161 Ronellenfitsch U, Jensen K, Seide S, Kieser M, Schwarzbach M, Slanger TE, Burmeister B, Kelsen D, Niedzwiecki D, Piessen G, Schuhmacher C, Urba S, van de Velde C, Ychou M, Hofheinz R, Lorenzen S. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. European Journal of Cancer 2019;123:101-11. [DOI: 10.1016/j.ejca.2019.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
162 Lajous H, Lelièvre B, Vauléon E, Lecomte P, Garcion E. Rethinking Alkylating(-Like) Agents for Solid Tumor Management. Trends Pharmacol Sci 2019;40:342-57. [PMID: 30979523 DOI: 10.1016/j.tips.2019.03.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
163 Cartwright E, Keane FK, Enzinger PC, Hong T, Chau I. Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma? American Society of Clinical Oncology Educational Book 2018. [DOI: 10.1200/edbk_200785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
164 Jung HK, Tae CH, Lee HA, Lee H, Don Choi K, Park JC, Kwon JG, Choi YJ, Hong SJ, Sung J, Chung WC, Kim KB, Kim SY, Song KH, Park KS, Jeon SW, Kim BW, Ryu HS, Lee OJ, Baik GH, Kim YS, Jung HY; Korean College of Helicobacter and Upper Gastrointestinal Research. Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients. PLoS One 2020;15:e0231456. [PMID: 32275699 DOI: 10.1371/journal.pone.0231456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
165 Mantziari S, Allemann P, Winiker M, Demartines N, Schäfer M. Locoregional Tumor Extension and Preoperative Smoking are Significant Risk Factors for Early Recurrence After Esophagectomy for Cancer. World J Surg 2018;42:2209-17. [DOI: 10.1007/s00268-017-4422-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
166 Marguet S, Adenis A, Delaine-Clisant S, Penel N, Bonastre J. Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial. Value Health 2021;24:676-82. [PMID: 33933236 DOI: 10.1016/j.jval.2020.11.017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Pucher PH, Rahman SA, Walker RC, Grace BL, Bateman A, Iveson T, Jackson A, Rees C, Byrne JP, Kelly JJ, Noble F, Underwood TJ. Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis. Eur J Surg Oncol 2020;46:2248-56. [PMID: 32694054 DOI: 10.1016/j.ejso.2020.06.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
168 Innocente R, Navarria F, Petri R, Palazzari E, Vecchiato M, Polesel J, Ziccarelli A, Martino A, Ubiali P, Tonin D, Lauretta A, Belluco C, Foltran L, Buonadonna A, Lleshi A, Colombo CB, Barresi L, Gigante M, Franchin G, De Paoli A. Feasibility and Oncological Outcome of Preoperative Chemoradiation With IMRT Dose Intensification for Locally Advanced Esophageal and Gastroesophageal Cancer. Front Oncol 2021;11:626275. [PMID: 33680967 DOI: 10.3389/fonc.2021.626275] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Wolfson P, Ho KMA, Bassett P, Haidry R, Olivo A, Lovat L, Sami SS. Accuracy of clinical staging for T2N0 oesophageal cancer: systematic review and meta-analysis. Dis Esophagus 2021;34:doab002. [PMID: 33618359 DOI: 10.1093/dote/doab002] [Reference Citation Analysis]
170 Michalarea V, Smyth EC. Neoadjuvant DCF vs. ACF for resectable oesophageal squamous cell carcinoma. J Thorac Dis 2017;9:2868-70. [PMID: 29221258 DOI: 10.21037/jtd.2017.08.148] [Reference Citation Analysis]
171 Cunha R, Godinho J, Inácio M, Galriça Neto I. Palliative approach to leptomeningeal carcinomatosis in oesophagogastric junction cancer. BMJ Case Rep 2019;12:e230114. [PMID: 31604716 DOI: 10.1136/bcr-2019-230114] [Reference Citation Analysis]
172 Peng W, Tu G, Zhao Z, He B, Cai Q, Zhang P, Peng X, Shi S, Wang X. DNA methylome and transcriptome analysis established a model of four differentially methylated positions (DMPs) as a diagnostic marker in esophageal adenocarcinoma early detection. PeerJ 2021;9:e11355. [PMID: 34012728 DOI: 10.7717/peerj.11355] [Reference Citation Analysis]
173 Kauppila JH, Helminen O, Kytö V, Gunn J, Lagergren J, Sihvo E. Short-Term Outcomes Following Minimally Invasive and Open Esophagectomy: A Population-Based Study from Finland and Sweden. Ann Surg Oncol 2018;25:326-32. [PMID: 29094248 DOI: 10.1245/s10434-017-6212-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
174 Jeremiasen M, Borg D, Hedner C, Svensson M, Nodin B, Leandersson K, Johansson J, Jirström K. Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma. Front Oncol 2020;10:534761. [PMID: 33194593 DOI: 10.3389/fonc.2020.534761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
175 Pischik VG. Editorial comments for neoadjuvant chemo-radiotherapy in the treatment of locally advanced squamous cell esophageal cancer. J Thorac Dis 2018;10:5979-81. [PMID: 30622767 DOI: 10.21037/jtd.2018.10.81] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
176 Wang HY, Zeng X, Bai SY, Pu K, Zheng Y, Ji R, Guo QH, Guan QL, Wang YP, Zhou YN. The safety and efficacy of endoscopic submucosal dissection for treating early oesophageal carcinoma: a meta-analysis. Ann R Coll Surg Engl 2020;102:702-11. [PMID: 32820658 DOI: 10.1308/rcsann.2020.0177] [Reference Citation Analysis]
177 Qin J, Zhu HD, Guo JH, Ni CF, Wu P, Xu H, Mao AW, Lu J, Su C, Teng GJ. Factors associated with overall survival and relief of dysphagia in advanced esophageal cancer patients after 125I seed-loaded stent placement: a multicenter retrospective analysis. Dis Esophagus 2019;32:doz012. [PMID: 30888392 DOI: 10.1093/dote/doz012] [Reference Citation Analysis]
178 Alberda C, Alvadj-korenic T, Mayan M, Gramlich L. Nutrition Care in Patients With Head and Neck or Esophageal Cancer: The Patient Perspective. Nutr Clin Pract 2017;32:664-74. [DOI: 10.1177/0884533617725050] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
179 Chiappa A, Andreoni B, Dionigi R, Spaggiari L, Foschi D, Polvani G, Orecchia R, Fazio N, Pravettoni G, Cossu ML, Galetta D, Venturino M, Ferrari C, Macone L, Crosta C, Bonanni B, Biffi R. A rationale multidisciplinary approach for treatment of esophageal and gastroesophageal junction cancer: Accurate review of management and perspectives. Crit Rev Oncol Hematol. 2018;132:161-168. [PMID: 30447922 DOI: 10.1016/j.critrevonc.2018.10.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
180 Yukawa N, Aoyama T, Tamagawa H, Tamagawa A, Atsumi Y, Kawahara S, Maezawa Y, Kano K, Murakawa M, Kazama K, Numata M, Oshima T, Masuda M, Rino Y. The Lymph Node Ratio Is an Independent Prognostic Factor in Esophageal Cancer Patients Who Receive Curative Surgery. In Vivo 2020;34:2087-93. [PMID: 32606187 DOI: 10.21873/invivo.12012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Celik E, Baus W, Baues C, Schröder W, Clivio A, Fogliata A, Scorsetti M, Marnitz S, Cozzi L. Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer. Radiat Oncol 2020;15:120. [PMID: 32448296 DOI: 10.1186/s13014-020-01570-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
182 Powell AGMT, Karran A, Blake P, Christian A, Roberts SA, Lewis WG. Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy. BJS Open 2020;4:593-600. [PMID: 32374504 DOI: 10.1002/bjs5.50287] [Reference Citation Analysis]
183 Sugawara K, Yagi K, Okumura Y, Nishida M, Aikou S, Yamashita H, Seto Y. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma. Int J Clin Oncol. 2020;25:552-560. [PMID: 31828451 DOI: 10.1007/s10147-019-01590-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
184 Goense L, Ruurda JP, Carter BW, Fang P, Ho L, Meijer GJ, van Hillegersberg R, Hofstetter WL, Lin SH. Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2018;45:1742-51. [PMID: 29663014 DOI: 10.1007/s00259-018-4011-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
185 Kroese TE, Goense L, van Hillegersberg R, de Keizer B, Mook S, Ruurda JP, van Rossum PSN. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis. Dis Esophagus 2018;31. [PMID: 29917073 DOI: 10.1093/dote/doy055] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
186 Koldby KM, Mortensen MB, Detlefsen S, Pfeiffer P, Thomassen M, Kruse TA. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients. J Gastroenterol 2019;54:108-21. [PMID: 30242476 DOI: 10.1007/s00535-018-1508-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
187 Jepsen DNM, Fiehn AK, Svendsen B, Achiam MP, Federspiel B. Isolated tumor cells in the regional lymph nodes in patients with squamous cell carcinoma of the esophagus are rarely observed but often represent part of a true metastasis. Ann Diagn Pathol 2020;45:151478. [PMID: 32135481 DOI: 10.1016/j.anndiagpath.2020.151478] [Reference Citation Analysis]
188 Kaech M, Deutschmann E, Moffa G, Haak F, Bucher HC, Kettelhack C, von Strauss Und Torney M. Influence of the introduction of caseload requirements on indication for visceral cancer surgery in Switzerland. Eur J Surg Oncol 2021;47:1324-31. [PMID: 33895025 DOI: 10.1016/j.ejso.2021.04.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Zhou HY, Zheng SP, Li AL, Gao QL, Ou QY, Chen YJ, Wu ST, Lin DG, Liu SB, Huang LY, Li FS, Zhu HY, Qiao GB, Lanuti M, Yao HR, Yu YF. Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study). EClinicalMedicine 2020;24:100422. [PMID: 32637899 DOI: 10.1016/j.eclinm.2020.100422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
190 Molina JC, Goudie E, Pollock C, Menezes V, Ferraro P, Lafontaine E, Martin J, Nasir B, Liberman M. Balloon Dilation for Endosonographic Staging in Esophageal Cancer: A Phase 1 Clinical Trial. Ann Thorac Surg 2021;111:1150-5. [PMID: 32866480 DOI: 10.1016/j.athoracsur.2020.06.063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
191 Wiseman D, Ferri L, Lakatos PL, Fiset PO, Bessissow T. Esophageal Squamous Cell Carcinoma With Colonic Metastases. ACG Case Rep J 2020;7:e00335. [PMID: 32309520 DOI: 10.14309/crj.0000000000000335] [Reference Citation Analysis]
192 Triantafyllou T, Olson MT, Theodorou D, Zografos G, Singhal S. Esophageal cancer: challenges, concerns, and recommendations for management amidst the COVID-19 pandemic. Ann Gastroenterol 2020;33:453-8. [PMID: 32879590 DOI: 10.20524/aog.2020.0519] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Depypere L, Thomas M, Moons J, Coosemans W, Lerut T, Prenen H, Haustermans K, Van Veer H, Nafteux P. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy. World J Surg Oncol 2019;17:89. [PMID: 31133018 DOI: 10.1186/s12957-019-1630-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
194 Larroquette M, Domblides C, Lefort F, Lasserre M, Quivy A, Sionneau B, Bertolaso P, Gross-Goupil M, Ravaud A, Daste A. Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. Eur J Cancer 2021;158:47-62. [PMID: 34655837 DOI: 10.1016/j.ejca.2021.09.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:1506-17. [PMID: 31582355 DOI: 10.1016/S1470-2045(19)30626-6] [Cited by in Crossref: 205] [Cited by in F6Publishing: 127] [Article Influence: 102.5] [Reference Citation Analysis]
196 Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH. 18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma. J Nucl Med 2017;58:1756-63. [PMID: 28522744 DOI: 10.2967/jnumed.117.192591] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
197 Schurink B, Mazza E, Ruurda JP, Roeling TAP, Bleys RLAW, van Hillegersberg R. Metastatic incidence of (PET)CT positive lung hilar and retroperitoneal lymph nodes in esophageal cancer patients. Surg Oncol 2020;33:170-6. [PMID: 32561084 DOI: 10.1016/j.suronc.2020.02.012] [Reference Citation Analysis]
198 Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, Mamon HJ, Moehler M, Fu X, Cho BC, Bordia S, Bhagia P, Shih CS, Desai A, Enzinger P. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol 2021;17:1143-53. [PMID: 33533655 DOI: 10.2217/fon-2020-0969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
199 Costa-Santos MP, Ferreira AO, Mouradides C, Pérez-Cuadrado-Robles E, Yeung R, Garcés-Duran R, Snauwaert C, Dano H, Piessevaux H, Deprez PH. Is Lugol necessary for endoscopic resection of esophageal squamous cell neoplasia? Endosc Int Open 2020;8:E1471-7. [PMID: 33043116 DOI: 10.1055/a-1198-4316] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Ilson DH, van Hillegersberg R. Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus. Gastroenterology 2018;154:437-51. [DOI: 10.1053/j.gastro.2017.09.048] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 12.7] [Reference Citation Analysis]
201 Jung MK, Schmidt T, Chon SH, Chevallay M, Berlth F, Akiyama J, Gutschow CA, Mönig SP. Current surgical treatment standards for esophageal and esophagogastric junction cancer.Ann N Y Acad Sci. 2020;1482:77-84. [PMID: 32798235 DOI: 10.1111/nyas.14454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Göbel HH, Büttner-Herold MJ, Fuhrich N, Aigner T, Grabenbauer GG, Distel LVR. Cytotoxic and immunosuppressive inflammatory cells predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma. Radiother Oncol 2020;146:151-60. [PMID: 32169773 DOI: 10.1016/j.radonc.2020.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Vollenbrock SE, Nowee ME, Voncken FEM, Kotte ANTJ, Goense L, van Rossum PSN, van Lier ALHMW, Heijmink SW, Bartels-Rutten A, Wessels FJ, Aleman BMP, Dewit L, Kerkmeijer LGW, Jansen EPM, Intven M, Lips IM, Meijer GJ, Nijkamp J. Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT. Adv Radiat Oncol 2019;4:596-604. [PMID: 31673653 DOI: 10.1016/j.adro.2019.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
204 Lordick F. More is more? Pushing chemoradiotherapy of oesophageal squamous cell carcinoma forward. Eur J Cancer 2018;97:25-6. [PMID: 29735378 DOI: 10.1016/j.ejca.2018.03.028] [Reference Citation Analysis]
205 Ahtiainen V, Vaalavirta L, Tenhunen M, Joensuu H, Mäenpää H. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up. Acta Oncol 2020;59:1064-71. [PMID: 32603613 DOI: 10.1080/0284186X.2020.1785003] [Reference Citation Analysis]
206 Götzel K, Chemnitzer O, Maurer L, Dietrich A, Eichfeld U, Lyros O, Moulla Y, Niebisch S, Mehdorn M, Jansen-Winkeln B, Vieth M, Hoffmeister A, Gockel I, Thieme R. In-depth characterization of the Wnt-signaling/β-catenin pathway in an in vitro model of Barrett's sequence. BMC Gastroenterol 2019;19:38. [PMID: 30841855 DOI: 10.1186/s12876-019-0957-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
207 Li CC, Chen CY, Chou YH, Huang CJ, Ku HY, Chien CR. Optimal radiotherapy dose in cervical esophageal squamous cell carcinoma patients treated with definitive concurrent chemoradiotherapy: A population based study. Thorac Cancer 2021;12:2065-71. [PMID: 34028200 DOI: 10.1111/1759-7714.14009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
208 Victor CR, Fujiki FK, Takeda FR, Hoff PMG, de Castria TB. Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil. J Glob Oncol 2019;5:1-10. [PMID: 31365299 DOI: 10.1200/JGO.19.00103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
209 Stout NL, Santa Mina D, Lyons KD, Robb K, Silver JK. A systematic review of rehabilitation and exercise recommendations in oncology guidelines. CA Cancer J Clin 2021;71:149-75. [PMID: 33107982 DOI: 10.3322/caac.21639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
210 Koemans WJ, van Dieren JM, van den Berg JG, Meijer GA, Snaebjornsson P, Chalabi M, Lecot F, Riedl R, Krijgsman O, Hofland I, Broeks A, Voncken FEM, Peppelenbosch MP, Sosef MN, van Sandick JW, Kodach LL. High CD8+ tumour-infiltrating lymphocyte density associates with unfavourable prognosis in oesophageal adenocarcinoma following poor response to neoadjuvant chemoradiotherapy. Histopathology 2021;79:238-51. [PMID: 33660299 DOI: 10.1111/his.14361] [Reference Citation Analysis]
211 Xi M, Zhang P, Zhang L, Yang YD, Liu SL, Li Y, Fu JH, Liu MZ. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. Jpn J Clin Oncol 2017;47:683-9. [PMID: 28453815 DOI: 10.1093/jjco/hyx060] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
212 Li C, Wang X, Wang X, Han C, Wang P, Pang Q, Chen J, Sun X, Wang L, Zhang W, Lin Y, Ge X, Zhou Z, Ni W, Chang X, Liang J, Deng L, Wang W, Zhao Y, Xiao Z. A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. BMC Cancer 2019;19:397. [PMID: 31036088 DOI: 10.1186/s12885-019-5544-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
213 Gao LR, Wang X, Han W, Deng W, Li C, Wang X, Zhao Y, Ni W, Chang X, Zhou Z, Deng L, Wang W, Liu W, Liang J, Zhang T, Bi N, Wang J, Zhai Y, Feng Q, Lv J, Li L, Xiao Z. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. BMC Cancer 2020;20:901. [PMID: 32962674 DOI: 10.1186/s12885-020-07387-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 de Vos-Geelen J, Geurts SM, van Putten M, Valkenburg-van Iersel LB, Grabsch HI, Haj Mohammad N, Hoebers FJ, Hoge CV, Jeene PM, de Jong EJ, van Laarhoven HW, Rozema T, Slingerland M, Tjan-Heijnen VC, Nieuwenhuijzen GA, Lemmens VE. Trends in treatment and overall survival among patients with proximal esophageal cancer. World J Gastroenterol 2019; 25(47): 6835-6846 [PMID: 31885424 DOI: 10.3748/wjg.v25.i47.6835] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
215 Xing W, Zhao L, Fu X, Liang G, Zhang Y, Yuan D, Li Z, Gao Q, Zheng Y; written on Henan Cancer Hospital Thoracic Oncology Group (HCHTOG). A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma. J Thorac Dis 2020;12:6861-7. [PMID: 33282388 DOI: 10.21037/jtd-20-2198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Capovilla G, Moletta L, Pierobon ES, Salvador R, Provenzano L, Zanchettin G, Costantini M, Merigliano S, Valmasoni M. Optimal Treatment of cT2N0 Esophageal Carcinoma: Is Upfront Surgery Really the Way? Ann Surg Oncol 2021. [PMID: 34142286 DOI: 10.1245/s10434-021-10194-9] [Reference Citation Analysis]
217 Saeki H, Sohda M, Sakai M, Sano A, Shirabe K. Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma. Ann Gastroenterol Surg 2020;4:490-7. [PMID: 33005843 DOI: 10.1002/ags3.12364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
218 Borggreve AS, Heethuis SE, Boekhoff MR, Goense L, van Rossum PSN, Brosens LAA, van Lier ALHMW, van Hillegersberg R, Lagendijk JJW, Mook S, Ruurda JP, Meijer GJ. Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer. Eur Radiol 2020;30:1896-907. [PMID: 31822974 DOI: 10.1007/s00330-019-06513-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
219 Niclauss N, Chevallay M, Frossard JL, Mönig SP. [Surgical strategy for early stage carcinoma of the esophagus]. Chirurg 2018;89:339-46. [PMID: 29392342 DOI: 10.1007/s00104-018-0589-2] [Reference Citation Analysis]
220 de Vries EGE, Kist de Ruijter L, Lub-de Hooge MN, Dierckx RA, Elias SG, Oosting SF. Integrating molecular nuclear imaging in clinical research to improve anticancer therapy. Nat Rev Clin Oncol 2019;16:241-55. [PMID: 30479378 DOI: 10.1038/s41571-018-0123-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
221 Schmidt T, Mönig SP. [Therapeutic approach in oligometastatic gastric and esophageal cancer]. Chirurg 2017;88:1024-32. [PMID: 29098307 DOI: 10.1007/s00104-017-0548-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
222 Morgan E, Soerjomataram I, Gavin AT, Rutherford MJ, Gatenby P, Bardot A, Ferlay J, Bucher O, De P, Engholm G, Jackson C, Kozie S, Little A, Møller B, Shack L, Tervonen H, Thursfield V, Vernon S, Walsh PM, Woods RR, Finley C, Merrett N, O'Connell DL, Reynolds JV, Bray F, Arnold M. International trends in oesophageal cancer survival by histological subtype between 1995 and 2014. Gut 2021;70:234-42. [PMID: 32554620 DOI: 10.1136/gutjnl-2020-321089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
223 Lonie JM, Barbour AP, Dolcetti R. Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches. Cancer Treat Rev 2021;98:102219. [PMID: 33993033 DOI: 10.1016/j.ctrv.2021.102219] [Reference Citation Analysis]
224 Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Bütof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Löck S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Pöttgen C, Rödel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zöphel K, Zschaeck S, Thorwarth D, Troost EGC; Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN. Value of PET imaging for radiation therapy. Strahlenther Onkol 2021;197:1-23. [PMID: 34259912 DOI: 10.1007/s00066-021-01812-2] [Reference Citation Analysis]
225 Bjerring OS, Fristrup CW, Pfeiffer P, Lundell L, Mortensen MB. Phase II randomized clinical trial of endosonography and PET/CT versus clinical assessment only for follow-up after surgery for upper gastrointestinal cancer (EUFURO study). British Journal of Surgery 2019;106:1761-8. [DOI: 10.1002/bjs.11290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
226 Markar SR, Gronnier C, Pasquer A, Duhamel A, Behal H, Théreaux J, Gagnière J, Lebreton G, Brigand C, Renaud F, Piessen G, Meunier B, Collet D, Mariette C; FREGAT Working Group—FRENCH—AFC. Discrepancy Between Clinical and Pathologic Nodal Status of Esophageal Cancer and Impact on Prognosis and Therapeutic Strategy. Ann Surg Oncol 2017;24:3911-20. [PMID: 28948524 DOI: 10.1245/s10434-017-6088-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
227 Xi M, Lin SH. Recent advances in intensity modulated radiotherapy and proton therapy for esophageal cancer. Expert Rev Anticancer Ther 2017;17:635-46. [PMID: 28503964 DOI: 10.1080/14737140.2017.1331130] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
228 Hagens ERC, van Berge Henegouwen MI, van Sandick JW, Cuesta MA, van der Peet DL, Heisterkamp J, Nieuwenhuijzen GAP, Rosman C, Scheepers JJG, Sosef MN, van Hillegersberg R, Lagarde SM, Nilsson M, Räsänen J, Nafteux P, Pattyn P, Hölscher AH, Schröder W, Schneider PM, Mariette C, Castoro C, Bonavina L, Rosati R, de Manzoni G, Mattioli S, Garcia JR, Pera M, Griffin M, Wilkerson P, Chaudry MA, Sgromo B, Tucker O, Cheong E, Moorthy K, Walsh TN, Reynolds J, Tachimori Y, Inoue H, Matsubara H, Kosugi SI, Chen H, Law SYK, Pramesh CS, Puntambekar SP, Murthy S, Linden P, Hofstetter WL, Kuppusamy MK, Shen KR, Darling GE, Sabino FD, Grimminger PP, Meijer SL, Bergman JJGHM, Hulshof MCCM, van Laarhoven HWM, Mearadji B, Bennink RJ, Annema JT, Dijkgraaf MGW, Gisbertz SS. Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study. BMC Cancer 2019;19:662. [PMID: 31272485 DOI: 10.1186/s12885-019-5761-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
229 Ikeda G, Yamamoto S, Kato K. The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy. Expert Opin Drug Saf 2021;:1-11. [PMID: 34263677 DOI: 10.1080/14740338.2021.1955100] [Reference Citation Analysis]
230 Coelho FDS, Barros DE, Santos FA, Meireles FC, Maia FC, Trovisco RA, Machado TM, Barbosa JA. Minimally invasive esophagectomy versus open esophagectomy: A systematic review and meta-analysis. Eur J Surg Oncol 2021:S0748-7983(21)00575-8. [PMID: 34148823 DOI: 10.1016/j.ejso.2021.06.012] [Reference Citation Analysis]
231 Becker J, Schwarzenböck SM, Krause BJ. FDG PET Hybrid Imaging. Recent Results Cancer Res 2020;216:625-67. [PMID: 32594401 DOI: 10.1007/978-3-030-42618-7_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
232 Larue RTHM, Klaassen R, Jochems A, Leijenaar RTH, Hulshof MCCM, van Berge Henegouwen MI, Schreurs WMJ, Sosef MN, van Elmpt W, van Laarhoven HWM, Lambin P. Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. Acta Oncol. 2018;57:1475-1481. [PMID: 30067421 DOI: 10.1080/0284186x.2018.1486039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
233 Yan W, Zhao P, Fu H, Lin Y, Li Z, Dai L, Yang Y, Kang X, Chen KN. Survival After Induction Chemotherapy and Esophagectomy Is Not Improved by Adjuvant Chemotherapy. Ann Thorac Surg 2019;108:1505-13. [PMID: 31233722 DOI: 10.1016/j.athoracsur.2019.04.106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
234 van Deudekom FJ, Klop HG, Hartgrink HH, Boonstra JJ, Lips IM, Slingerland M, Mooijaart SP. Functional and cognitive impairment, social functioning, frailty and adverse health outcomes in older patients with esophageal cancer, a systematic review. J Geriatr Oncol 2018;9:560-8. [PMID: 29680585 DOI: 10.1016/j.jgo.2018.03.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
235 Vellayappan BA, Soon YY, Ku GY, Leong CN, Lu JJ, Tey JC. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. Cochrane Database Syst Rev 2017;8:CD010511. [PMID: 28829911 DOI: 10.1002/14651858.CD010511.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
236 Zhang Y, Liu J, Zhang W, Deng W, Yue J. Treatment of esophageal cancer with radiation therapy -a pan-Chinese survey of radiation oncologists. Oncotarget 2017;8:34946-53. [PMID: 28430590 DOI: 10.18632/oncotarget.16858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
237 Swords DS, Mulvihill SJ, Brooke BS, Firpo MA, Scaife CL. Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers. Ann Surg Oncol 2020;27:333-41. [DOI: 10.1245/s10434-019-07922-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
238 Borggreve AS, Goense L, van Rossum PSN, Heethuis SE, van Hillegersberg R, Lagendijk JJW, Lam MGEH, van Lier ALHMW, Mook S, Ruurda JP, van Vulpen M, Voncken FEM, Aleman BMP, Bartels-Rutten A, Ma J, Fang P, Musall BC, Lin SH, Meijer GJ. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using 18F-FDG PET/CT and DW-MRI: A Prospective Multicenter Study. Int J Radiat Oncol Biol Phys 2020;106:998-1009. [PMID: 31987972 DOI: 10.1016/j.ijrobp.2019.12.038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
239 Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048. [PMID: 28748917 DOI: 10.1038/nrdp.2017.48] [Cited by in Crossref: 249] [Cited by in F6Publishing: 246] [Article Influence: 62.3] [Reference Citation Analysis]
240 Zhao K, Wang C, Mao Q, Shang D, Huang Y, Ma L, Yu J, Li M. The flow-metabolism ratio might predict treatment response and survival in patients with locally advanced esophageal squamous cell carcinoma. EJNMMI Res 2020;10:57. [PMID: 32472227 DOI: 10.1186/s13550-020-00647-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
241 Tu CC, Hsu PK. The frontline of esophageal cancer treatment: questions to be asked and answered. Ann Transl Med 2018;6:83. [PMID: 29666806 DOI: 10.21037/atm.2017.10.31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
242 Junttila A, Helminen O, Mrena J, Sihvo E. Exercise capacity in the stair-climbing test predicts outcomes of operable esophageal cancer in minimally invasive era. Eur J Surg Oncol 2021:S0748-7983(21)00774-5. [PMID: 34740478 DOI: 10.1016/j.ejso.2021.10.024] [Reference Citation Analysis]
243 van der Bogt R, Vermeulen B, Reijm A, Siersema P, Spaander M. Palliation of dysphagia. Best Practice & Research Clinical Gastroenterology 2018;36-37:97-103. [DOI: 10.1016/j.bpg.2018.11.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
244 Hoeppner J. Hybrid Minimally Invasive Esophagectomy: How I Teach It. Ann Thorac Surg 2021;112:10-5. [PMID: 33684348 DOI: 10.1016/j.athoracsur.2021.02.050] [Reference Citation Analysis]
245 Yamamoto S, Kato K. Pembrolizumab for the treatment of esophageal cancer. Expert Opin Biol Ther 2020;20:1143-50. [PMID: 32620063 DOI: 10.1080/14712598.2020.1792881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
246 Sun X, Wang L, Wang Y, Kang J, Jiang W, Men Y, Hui Z. High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis. Front Oncol 2020;10:1222. [PMID: 32850362 DOI: 10.3389/fonc.2020.01222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
247 Powell AGMT, Chin C, Coxon AH, Chalishazar A, Christian A, Roberts SA, Lewis WG. Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma. BJS Open 2020;4:416-23. [PMID: 32232963 DOI: 10.1002/bjs5.50277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
248 Aoyama T, Atsumi Y, Hara K, Tamagawa H, Tamagawa A, Komori K, Hashimoto I, Maezawa Y, Kazama K, Kano K, Murakawa M, Numata M, Oshima T, Yukawa N, Masuda M, Rino Y. Risk Factors for Postoperative Anastomosis Leak After Esophagectomy for Esophageal Cancer. In Vivo 2020;34:857-62. [PMID: 32111795 DOI: 10.21873/invivo.11849] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
249 Piegeler T, Stehr SN, Pfirrmann D, Knödler M, Lordick F, Mehnert A, Selig L, Weimann A, Mehdorn M, Gockel I, Simon P. [Special situations of preconditioning and prehabilitation in oncological visceral surgery]. Chirurg 2018;89:903-8. [PMID: 30377726 DOI: 10.1007/s00104-018-0708-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
250 Bascoul-Mollevi C, Gourgou S, Galais MP, Raoul JL, Bouché O, Douillard JY, Adenis A, Etienne PL, Juzyna B, Bedenne L, Conroy T. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. Eur J Cancer 2017;84:239-49. [PMID: 28829992 DOI: 10.1016/j.ejca.2017.07.038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
251 Motoyama S, Sato Y, Wakita A, Nagaki Y, Fujita H, Sasamori R, Kemuriyama K, Takashima S, Imai K, Minamiya Y. Lower local recurrence rate after robot-assisted thoracoscopic esophagectomy than conventional thoracoscopic surgery for esophageal cancer. Sci Rep 2021;11:6774. [PMID: 33762693 DOI: 10.1038/s41598-021-86420-x] [Reference Citation Analysis]
252 Li R, Shinde A, Glaser S, Chao J, Kim J, Karam SD, Goodman K, Chen YJ, Amini A. Analyzing the impact of neoadjuvant radiation dose on pathologic response and survival outcomes in esophageal and gastroesophageal cancers. J Gastrointest Oncol. 2019;10:712-722. [PMID: 31392052 DOI: 10.21037/jgo.2019.02.18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Helminen O, Valo J, Andersen H, Söderström J, Sihvo E. Extended resections and other special cases in lung cancer surgery: Real-world population-based outcomes. Thorac Cancer 2020;11:2932-40. [PMID: 32871056 DOI: 10.1111/1759-7714.13638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A, Imamura Y. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today 2020;50:12-20. [PMID: 31535225 DOI: 10.1007/s00595-019-01878-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 20.0] [Reference Citation Analysis]
255 Visaggi P, Barberio B, Ghisa M, Ribolsi M, Savarino V, Fassan M, Valmasoni M, Marchi S, de Bortoli N, Savarino E. Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence. Cancers (Basel) 2021;13:3162. [PMID: 34202763 DOI: 10.3390/cancers13133162] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
256 Kato K, Ito Y, Nozaki I, Daiko H, Kojima T, Yano M, Ueno M, Nakagawa S, Takagi M, Tsunoda S, Abe T, Nakamura T, Okada M, Toh Y, Shibuya Y, Yamamoto S, Katayama H, Nakamura K, Kitagawa Y; Japan Esophageal Oncology Group of the Japan Clinical Oncology Group. Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology 2021:S0016-5085(21)03352-7. [PMID: 34389340 DOI: 10.1053/j.gastro.2021.08.007] [Reference Citation Analysis]
257 Noordman B, Verdam M, Lagarde S, Shapiro J, Hulshof M, van Berge Henegouwen M, Wijnhoven B, Nieuwenhuijzen G, Bonenkamp J, Cuesta M, Plukker J, Spillenaar Bilgen E, Steyerberg E, van der Gaast A, Sprangers M, van Lanschot J. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial. Annals of Oncology 2018;29:445-51. [DOI: 10.1093/annonc/mdx726] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
258 Turgeman I, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021;9:903. [PMID: 34164537 DOI: 10.21037/atm.2020.03.110] [Reference Citation Analysis]
259 de Vos-Geelen J, Hoebers FJP, Geurts SME, Hoeben A, de Greef BTA, Voncken FEM, Bogers JHA, Braam PM, Muijs CKT, de Jong MA, Kasperts N, Rozema T, Jeene PM, Blom GJ, van Dieren JM, Hulshof MCCM, van Laarhoven HWM, Grabsch HI, Lemmens VEPP, Tjan-Heijnen VCG, Nieuwenhuijzen GAP. A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. Acta Oncol 2020;59:895-903. [PMID: 32319845 DOI: 10.1080/0284186X.2020.1753889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
260 Park JK, Kim JJ, Moon SW, Cho DG. Validity of upfront surgery for patients with unsuspected lymph node metastasis in esophageal cancer: a propensity scoring matching study. J Cardiothorac Surg 2018;13:62. [PMID: 29880029 DOI: 10.1186/s13019-018-0757-y] [Reference Citation Analysis]
261 Zheng Y, Liu XB, Sun HB, Xu J, Shen S, Ba YF, Yan M, Qin Z, Liu BX, Wang ZF, Liu SL, Zhang RX, Chen PN, Liang GH, Yuan D, Li ZX, Liu Q, Wang HR, Li HM, Lv H, Ma X, Zhu J, Yu YK, Xing WQ; written on Henan Cancer Hospital Thoracic Oncology Group (HCHTOG). A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909). Ann Transl Med 2021;9:73. [PMID: 33553366 DOI: 10.21037/atm-20-5404] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
262 Min LA, Castagnoli F, Vogel WV, Vellenga JP, van Griethuysen JJM, Lahaye MJ, Maas M, Beets Tan RGH, Lambregts DMJ. A decade of multi-modality PET and MR imaging in abdominal oncology. Br J Radiol 2021;:20201351. [PMID: 34387508 DOI: 10.1259/bjr.20201351] [Reference Citation Analysis]
263 Wang KL, Chen XL, Lei L, Li P, Hong LL, Huang XC, Mao WM, Mukaisho K, Ling ZQ. Validation study of susceptibility loci for esophageal squamous cell carcinoma identified by GWAS in a Han Chinese subgroup from Eastern China. J Cancer 2019;10:3624-31. [PMID: 31333779 DOI: 10.7150/jca.32810] [Reference Citation Analysis]
264 Mantziari S, Pomoni A, Prior JO, Winiker M, Allemann P, Demartines N, Schäfer M. 18F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer. BMC Med Imaging 2020;20:7. [PMID: 31969127 DOI: 10.1186/s12880-019-0401-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
265 Lin D, Chen X, Tan L. The predictive value of microRNAs for pathological response after neoadjuvant treatment in esophageal squamous cell carcinoma: a systematic review. Ann Transl Med 2021;9:420. [PMID: 33842641 DOI: 10.21037/atm-20-3000] [Reference Citation Analysis]
266 Nangraj AS, Selvaraj G, Kaliamurthi S, Kaushik AC, Cho WC, Wei DQ. Integrated PPI- and WGCNA-Retrieval of Hub Gene Signatures Shared Between Barrett's Esophagus and Esophageal Adenocarcinoma. Front Pharmacol 2020;11:881. [PMID: 32903837 DOI: 10.3389/fphar.2020.00881] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
267 Asadi-Lari M, Homaee-Shandiz F, Esmaeili-Hesari A. Changes in health-related quality of life in oesophagogastric cancer patients participating in palliative and curative therapies. Med J Islam Repub Iran 2018;32:31. [PMID: 30159282 DOI: 10.14196/mjiri.32.31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
268 Graham-Wisener L, Collins L, Hanna J, Dempster M. The need for enhanced psychological support in esophageal cancer-an exploratory study of the perception of HCPs, patients, and carers. Dis Esophagus 2019;32:doy076. [PMID: 30124801 DOI: 10.1093/dote/doy076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
269 Spence AD, Trainor J, McMenamin Ú, Turkington RC, McQuaid S, Bingham V, James J, Salto-Tellez M, McManus DT, Johnston BT, Cardwell CR, Coleman HG. High PTGS2 expression in post-neoadjuvant chemotherapy-treated oesophageal adenocarcinoma is associated with improved survival: a population-based cohort study. Histopathology 2019;74:587-96. [PMID: 30408225 DOI: 10.1111/his.13786] [Reference Citation Analysis]
270 Koenig A, Krug S, Mueller D, Barth PJ, Koenig U, Scharf M, Ellenrieder V, Michl P, Moll R, Homayunfar K, Kann PH, Stroebel P, Gress TM, Rinke A. Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms. PLoS One 2017;12:e0188876. [PMID: 29232390 DOI: 10.1371/journal.pone.0188876] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
271 Mikuni H, Yamamoto S, Kato K. Nivolumab for the treatment of esophageal cancer. Expert Opin Biol Ther 2021;21:697-703. [PMID: 33736560 DOI: 10.1080/14712598.2021.1904887] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
272 Okunaka M, Kotani D, Demachi K, Fujiwara H, Sakashita S, Yoshino T, Fujita T, Kojima T. Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy. Esophagus 2021. [PMID: 34611830 DOI: 10.1007/s10388-021-00885-3] [Reference Citation Analysis]
273 Moral Moral GI, Viana Miguel M, Vidal Doce Ó, Martínez Castro R, Parra López R, Palomo Luquero A, Cardo Díez MJ, Sánchez Pedrique I, Santos González J, Zanfaño Palacios J. Complicaciones postoperatorias y supervivencia del cáncer de esófago: análisis de dos periodos distintos. Cirugía Española 2018;96:473-81. [DOI: 10.1016/j.ciresp.2018.05.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
274 Aoyama T, Atsumi Y, Kawahara S, Tamagawa H, Tamagawa A, Ozawa Y, Maezawa Y, Kano K, Murakawa M, Kazama K, Segami K, Hara K, Numata M, Oshima T, Yukawa N, Masuda M, Rino Y. The Clinical Impact of the Age-adjusted Charlson Comorbidity Index on Esophageal Cancer Patients Who Receive Curative Treatment. In Vivo 2020;34:2783-90. [PMID: 32871815 DOI: 10.21873/invivo.12103] [Reference Citation Analysis]
275 Zhao P, Yan W, Fu H, Lin Y, Chen KN. Efficacy of postoperative adjuvant chemotherapy for esophageal squamous cell carcinoma: A meta-analysis. Thorac Cancer 2018;9:1048-55. [PMID: 29927075 DOI: 10.1111/1759-7714.12787] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
276 Lee J, Choi JY, Lim SW, Ahn MJ, Park K, Zo JI, Shim YM, Oh D, Sun JM. Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation. Eur J Cardiothorac Surg 2020;58:1019-26. [PMID: 32920638 DOI: 10.1093/ejcts/ezaa181] [Reference Citation Analysis]
277 Labgaa I, Mantziari S, Genety M, Elliott JA, Kamiya S, Kalff MC, Winiker M, Pasquier J, Allemann P, Messier M, van Berge Henegouwen MI, Nilsson M, Reynolds JV, Piessen G, Hübner M, Demartines N, Schäfer M. Early postoperative decrease of albumin is an independent predictor of major complications after oncological esophagectomy: A multicenter study. J Surg Oncol 2021;123:462-9. [PMID: 33289149 DOI: 10.1002/jso.26317] [Reference Citation Analysis]
278 Paireder M, Jomrich G, Kristo I, Asari R, Rieder E, Beer A, Ilhan-Mutlu A, Preusser M, Schmid R, Schoppmann SF. Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity. Strahlenther Onkol 2020;196:779-86. [PMID: 32055873 DOI: 10.1007/s00066-020-01594-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
279 Chen M, Liu P, Chen Y, Chen Z, Shen M, Liu X, Li X, Lin Y, Yang R, Ni W, Zhou X, Zhang L, Tian Y, Chen J. Primary tumor regression patterns in esophageal squamous cell cancer treated with definitive chemoradiotherapy and implications for surveillance schemes. Cancer Manag Res. 2019;11:3361-3369. [PMID: 31114372 DOI: 10.2147/cmar.s198524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
280 Yap W, Chang Y, Hsieh C, Chao Y, Chen C, Shih M, Hung T. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Eur J Nucl Med Mol Imaging 2018;45:689-98. [DOI: 10.1007/s00259-017-3901-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
281 Li Y, Liu H, Sun C, Yin X, Tong J, Zhang X, Wang X, Yuan X, Zhang Z, Lu G, Gu Y, Li Y, Huang T, Qiao Z, Chen Y. Comparison of Clinical Efficacy of Neoadjuvant Chemoradiation Therapy Between Lower and Higher Radiation Doses for Carcinoma of the Esophagus and Gastroesophageal Junction: A Systematic Review. Int J Radiat Oncol Biol Phys 2021;111:405-16. [PMID: 33964352 DOI: 10.1016/j.ijrobp.2021.04.031] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
282 Gruber ES, Oberhuber G, Birner P, Schlederer M, Kenn M, Schreiner W, Jomrich G, Schoppmann SF, Gnant M, Tse W, Kenner L. The Oncogene AF1Q is Associated with WNT and STAT Signaling and Offers a Novel Independent Prognostic Marker in Patients with Resectable Esophageal Cancer. Cells 2019;8:E1357. [PMID: 31671695 DOI: 10.3390/cells8111357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
283 Dworczak M, Le Deley MC, Adenis A, Piessen G, Lartigau É, Mirabel X, Lacornerie T, Pasquier D. [Dosimetric factors related to postoperative pulmonary complications in locally advanced esophageal cancers treated with preoperative chemoradiotherapy: Literature review]. Bull Cancer 2020;107:982-90. [PMID: 32977935 DOI: 10.1016/j.bulcan.2020.07.001] [Reference Citation Analysis]
284 Luo H, Cui YY, Zhang JG, Sun YN, Zheng XL, Yang CL, Ye K, Ge H. Meta-analysis of survival benefit with postoperative chemoradiotherapy in patients of lymph node positive esophageal carcinoma. Clin Transl Oncol 2018;20:889-98. [PMID: 29143229 DOI: 10.1007/s12094-017-1803-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
285 Kuvendjiska J, Marjanovic G, Glatz T, Kulemann B, Hoeppner J. Hybrid Minimally Invasive Esophagectomy-Surgical Technique and Results. J Clin Med 2019;8:E978. [PMID: 31284370 DOI: 10.3390/jcm8070978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
286 Levy A, Wagner AD, Chargari C, Moehler M, Verheij M, Durand-Labrunie J, Kissel M, Chirat E, Burtin P, Ducreux M, Boige V, Nilsson M, Boku N, Chau I, Deutsch E. Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. Eur J Cancer 2020;135:103-12. [PMID: 32563014 DOI: 10.1016/j.ejca.2020.04.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
287 Aoyama T, Atsumi Y, Kawahara S, Tamagawa H, Tamagawa A, Maezawa Y, Kano K, Murakawa M, Kazama K, Numata M, Oshima T, Yukawa N, Masuda M, Rino Y. The Number of Harvested LNs Is an Independent Prognostic Factor in Lymph Node Metastasis-negative Patients Who Received Curative Esophagectomy. In Vivo 2020;34:2021-7. [PMID: 32606176 DOI: 10.21873/invivo.12001] [Reference Citation Analysis]
288 Pathak R, Canavan ME, Walters S, Salazar MC, Boffa DJ. Chemoradiation as a nonsurgical treatment option for early-stage esophageal cancers: a retrospective cohort study. J Thorac Dis 2021;13:140-8. [PMID: 33569194 DOI: 10.21037/jtd-20-1187] [Reference Citation Analysis]
289 Su C, Liu W, Jiang T, Liu J. miR-488-5p promotes esophageal squamous cell carcinoma progression by suppressing the P53 pathway. J Thorac Dis 2021;13:5534-45. [PMID: 34659819 DOI: 10.21037/jtd-21-1448] [Reference Citation Analysis]
290 Schizas D, Kosmopoulos M, Giannopoulos S, Giannopoulos S, Kokkinidis DG, Karampetsou N, Papanastasiou CA, Rouvelas I, Liakakos T. Meta-analysis of risk factors and complications associated with atrial fibrillation after oesophagectomy. British Journal of Surgery 2019;106:534-47. [DOI: 10.1002/bjs.11128] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
291 Dröge LH, Karras PJ, Guhlich M, Schirmer MA, Ghadimi M, Rieken S, Conradi LC, Leu M. Preoperative Radiochemotherapy in Esophageal Squamous Cell Cancer with 5-Fluorouracil/Cisplatin or Carboplatin/Paclitaxel: Treatment Practice over a 20-Year Period and Implications for the Individual Treatment Modalities. Cancers (Basel) 2021;13:1834. [PMID: 33921384 DOI: 10.3390/cancers13081834] [Reference Citation Analysis]
292 Rasmussen SR, Nielsen RV, Fenger AS, Siemsen M, Ravn HB. Postoperative complications and survival after surgical resection of esophageal squamous cell carcinoma. J Thorac Dis 2018;10:4052-60. [PMID: 30174848 DOI: 10.21037/jtd.2018.07.04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
293 Tang Q, Wu L, Xu M, Yan D, Shao J, Yan S. Osalmid, a Novel Identified RRM2 Inhibitor, Enhances Radiosensitivity of Esophageal Cancer. Int J Radiat Oncol Biol Phys 2020;108:1368-79. [PMID: 32763454 DOI: 10.1016/j.ijrobp.2020.07.2322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
294 Cheng S, Yang L, Dai X, Wang J, Han X. The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database. BMC Cancer 2021;21:1057. [PMID: 34563149 DOI: 10.1186/s12885-021-08802-8] [Reference Citation Analysis]
295 Xu M, Wang L, Ouyang M, Lin J, Wang L, Zheng X, Miao S, Tang K. Prediction of lymph node metastasis by PET/CT metabolic parameters in patients with esophageal squamous cell carcinoma. Nucl Med Commun 2019;40:933-9. [PMID: 31343610 DOI: 10.1097/MNM.0000000000001050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
296 Chen MJ, Wu IC, Chen YJ, Wang TE, Chang YF, Yang CL, Huang WC, Chang WK, Sheu BS, Wu MS, Lin JT, Chu CH. Nutrition therapy in esophageal cancer-Consensus statement of the Gastroenterological Society of Taiwan. Dis Esophagus. 2018;31. [PMID: 29860406 DOI: 10.1093/dote/doy016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
297 Zhang R, Zou J, Li P, Li Q, Qiao Y, Han J, Huang K, Ruan P, Lin H, Song Q, Fu Z. Surgery to the primary tumor is associated with improved survival of patients with metastatic esophageal cancer: propensity score-matched analyses of a large retrospective cohort. Diseases of the Esophagus 2019. [DOI: 10.1093/dote/doz051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
298 Jin Z, Shen J, Wang C, Chen D, Zhang B, Zhang J, Ajani JA, Bennouna J, Chao J, Yoon HH, Zhu H, Ruan Y, Zhu C, Xu A. Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. Ann Transl Med 2021;9:1189. [PMID: 34430630 DOI: 10.21037/atm-21-2804] [Reference Citation Analysis]
299 Saviaro H, Rintala J, Kauppila JH, Yannopoulos F, Meriläinen S, Koivukangas V, Huhta H, Helminen O, Saarnio J. Thirty years of esophageal cancer surgery in Oulu University Hospital. J Thorac Dis 2021;13:4638-49. [PMID: 34527305 DOI: 10.21037/jtd-21-520] [Reference Citation Analysis]
300 Leers JM, Knepper L, van der Veen A, Schröder W, Fuchs H, Schiller P, Hellmich M, Zettelmeyer U, Brosens LAA, Quaas A, Ruurda JP, van Hillegersberg R, Bruns CJ. The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II. BMC Cancer 2020;20:781. [PMID: 32819399 DOI: 10.1186/s12885-020-07152-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
301 Attia H, Smyth E. Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy. Expert Rev Anticancer Ther 2021;21:535-46. [PMID: 33349073 DOI: 10.1080/14737140.2021.1866548] [Reference Citation Analysis]
302 Edwards P, Davidson M, Calamai V, Cunningham D, Starling N. Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends. Cancer Treat Rev 2018;71:32-8. [PMID: 30343173 DOI: 10.1016/j.ctrv.2018.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
303 Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho B, Nor I, Ng M, Chen L-, Kato K, Li J, Ryu M-, Zamaniah WIW, Yong W-, Yeh K-, Nakajima T, Shitara K, Kawakami H, Narita Y, Yoshino T, Van Cutsem E, Martinelli E, Smyth E, Arnold D, Minami H, Tabernero J, Douillard J-. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Annals of Oncology 2019;30:34-43. [DOI: 10.1093/annonc/mdy498] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 15.5] [Reference Citation Analysis]
304 Oh D, Kim JH. The Current Evidence on Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Korean J Thorac Cardiovasc Surg 2020;53:160-7. [PMID: 32793446 DOI: 10.5090/kjtcs.2020.53.4.160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
305 Fukahori M, Kato K, Taniguchi H, Ohtomo R, Takahashi N, Shoji H, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Yamada Y, Shimada Y, Ito Y, Itami J, Hokamura N, Igaki H, Tachimori Y, Miwa K, Torimura T, Boku N. Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations. Mol Clin Oncol 2021;14:41. [PMID: 33437479 DOI: 10.3892/mco.2020.2205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
306 Kuo YH, Chien YW, Chen PR, Feng CL, Li CC, Chien CR. Impact of the interval between neoadjuvant concurrent chemoradiotherapy and esophagectomy in the modern era: a population-based propensity-score-matched retrospective cohort study in Asia. World J Surg Oncol 2019;17:222. [PMID: 31856840 DOI: 10.1186/s12957-019-1712-7] [Reference Citation Analysis]
307 Zhao S, Qi W, Chen J. Role of a multidisciplinary team in administering radiotherapy for esophageal cancer. BMC Cancer 2020;20:974. [PMID: 33032547 DOI: 10.1186/s12885-020-07467-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
308 Tamaoki M, Yokoyama A, Horimatsu T, Hirohashi K, Amanuma Y, Higuchi H, Mitani Y, Yoshioka M, Ohashi S, Muto M. Repeated talaporfin sodium photodynamic therapy for esophageal cancer: safety and efficacy. Esophagus 2021;18:817-24. [PMID: 34106353 DOI: 10.1007/s10388-021-00853-x] [Reference Citation Analysis]
309 Petrelli F, Ghidini M, Barni S, Sgroi G, Passalacqua R, Tomasello G. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. Gastric Cancer. 2019;22:245-254. [PMID: 30483986 DOI: 10.1007/s10120-018-0901-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
310 Hewitt LC, Inam IZ, Saito Y, Yoshikawa T, Quaas A, Hoelscher A, Bollschweiler E, Fazzi GE, Melotte V, Langley RE, Nankivell M, Cunningham D, Allum W, Hutchins GG, Grabsch HI. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. Eur J Cancer 2018;94:104-14. [PMID: 29550565 DOI: 10.1016/j.ejca.2018.02.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
311 Hirose T, Yamamoto S, Kato K. Emerging data on nivolumab for esophageal squamous cell carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:845-54. [PMID: 34251958 DOI: 10.1080/17474124.2021.1948836] [Reference Citation Analysis]
312 Zhou S, Zhang L, Luo L, Li Q, Shen J, Feng Z, Feng Y, Yang H, Liu M, Xi M. Failure pattern of elective nodal irradiation for esophageal squamous cell cancer treated with neoadjuvant chemoradiotherapy. Jpn J Clin Oncol 2018;48:815-21. [PMID: 30053015 DOI: 10.1093/jjco/hyy099] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
313 Thomas M, Borggreve AS, van Rossum PSN, Perneel C, Moons J, Van Daele E, van Hillegersberg R, Deng W, Pattyn P, Mook S, Boterberg T, Ruurda JP, Nafteux P, Lin SH, Haustermans K. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis. Acta Oncol 2019;58:1358-65. [PMID: 31432736 DOI: 10.1080/0284186X.2019.1646432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
314 Tchelebi LT, Haustermans K, Scorsetti M, Hosni A, Huguet F, Hawkins MA, Dawson LA, Goodman KA. Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. Radiother Oncol. 2020;148:194-200. [PMID: 32342878 DOI: 10.1016/j.radonc.2020.04.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 27.0] [Reference Citation Analysis]
315 Decazes P, Thureau S, Modzelewski R, Damilleville-Martin M, Bohn P, Vera P. Benefits of positron emission tomography scans for the evaluation of radiotherapy. Cancer Radiother 2020;24:388-97. [PMID: 32448741 DOI: 10.1016/j.canrad.2020.02.007] [Reference Citation Analysis]
316 van den Ende T, Hulshof MCCM, van Berge Henegouwen MI, van Oijen MGH, van Laarhoven HWM. Gastro-oesophageal junction: to FLOT or to CROSS? Acta Oncol 2020;59:233-6. [PMID: 31813320 DOI: 10.1080/0284186X.2019.1698765] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
317 Thomas M, Mortensen HR, Hoffmann L, Møller DS, Troost EGC, Muijs CT, Berbee M, Bütof R, Nicholas O, Radhakrishna G, Defraene G, Nafteux P, Nordsmark M, Haustermans K. Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer. Radiother Oncol 2021;156:102-12. [PMID: 33285194 DOI: 10.1016/j.radonc.2020.11.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
318 Sundar R, Ng A, Zouridis H, Padmanabhan N, Sheng T, Zhang S, Lee MH, Ooi WF, Qamra A, Inam I, Hewitt LC, So JB, Koh V, Nankivell MG, Langley RE, Allum WH, Cunningham D, Rozen SG, Yong WP, Grabsch HI, Tan P. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. Eur J Cancer 2019;123:48-57. [PMID: 31655359 DOI: 10.1016/j.ejca.2019.09.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
319 Mantziari S, Allemann P, Winiker M, Sempoux C, Demartines N, Schäfer M. Sterilization of tumor-positive lymph nodes of esophageal cancer by neo-adjuvant treatment is associated with worse survival compared to tumor-negative lymph nodes treated with surgery first. J Surg Oncol 2017;116:524-32. [PMID: 28542983 DOI: 10.1002/jso.24689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
320 Valkema MJ, Noordman BJ, Wijnhoven BPL, Spaander MCW, Biermann K, Lagarde SM, Bennink RJ, Schreurs WMJ, Roef MJ, Hobbelink MGG, Janssen MJR, Graven LH, van Lanschot JJB, Valkema R. Accuracy of 18F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. J Nucl Med 2019;60:1553-9. [PMID: 30877177 DOI: 10.2967/jnumed.118.224196] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
321 Belmouhand M, Svendsen LB, Kofoed SC, Normann G, Baeksgaard L, Achiam MP. Recurrence following curative intended surgery for an adenocarcinoma in the gastroesophageal junction: a retrospective study. Dis Esophagus 2018;31. [PMID: 29228216 DOI: 10.1093/dote/dox136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
322 Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch OR, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar Bilgen EJ, van der Sangen MJC, Rozema T, Ten Kate FJW, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS Study Group. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol 2021;39:1995-2004. [PMID: 33891478 DOI: 10.1200/JCO.20.03614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
323 Maharaj AD, Holland JF, Scarborough RO, Evans SM, Ioannou LJ, Brown W, Croagh DG, Pilgrim CHC, Kench JG, Lipton LR, Leong T, McNeil JJ, Nikfarjam M, Aly A, Burton PR, Cashin PA, Chu J, Duong CP, Evans P, Goldstein D, Haydon A, Hii MW, Knowles BPF, Merrett ND, Michael M, Neale RE, Philip J, Porter IWT, Smith M, Spillane J, Tagkalidis PP, Zalcberg JR. The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers. BMJ Open 2019;9:e031434. [PMID: 31575580 DOI: 10.1136/bmjopen-2019-031434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
324 Faiz Z, van Putten M, Verhoeven RHA, van Sandick JW, Nieuwenhuijzen GAP, van der Sangen MJC, Lemmens VEPP, Wijnhoven BPL, Plukker JTM. Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer. Ann Surg Oncol 2019;26:986-95. [PMID: 30719634 DOI: 10.1245/s10434-019-07181-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
325 Cheng J, Cai M, Shuai X, Gao J, Wang G, Tao K. Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol 2019;11:1758835919838963. [PMID: 31044021 DOI: 10.1177/1758835919838963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
326 Luijten JCHBM, Nieuwenhuijzen GAP, Sosef MN, de Hingh IHJT, Rosman C, Ruurda JP, van Duijvendijk P, Heisterkamp J, de Steur WO, van Laarhoven HWM, Besselink MG, Groot Koerkamp B, van Santvoort HC, Lemmens VEP, Vissers PAJ. Impact of nationwide centralization of oesophageal, gastric, and pancreatic surgery on travel distance and experienced burden in the Netherlands. Eur J Surg Oncol 2021:S0748-7983(21)00645-4. [PMID: 34366174 DOI: 10.1016/j.ejso.2021.07.023] [Reference Citation Analysis]
327 De Mello RA, Lordick F, Muro K, Janjigian YY. Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. Am Soc Clin Oncol Educ Book 2019;39:237-47. [PMID: 31099644 DOI: 10.1200/EDBK_236699] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
328 van den Boorn HG, Abu-Hanna A, Ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MAG, Verhoeven RHA, Zwinderman AH, van Oijen MGH, van Laarhoven HWM. SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. Cancers (Basel) 2019;11:E187. [PMID: 30764578 DOI: 10.3390/cancers11020187] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
329 Lin CC, Doi T, Muro K, Hou MM, Esaki T, Hara H, Chung HC, Helwig C, Dussault I, Osada M, Kondo S. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. Target Oncol 2021;16:447-59. [PMID: 33840050 DOI: 10.1007/s11523-021-00810-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
330 Liu Q, Zhu Z, Chen Y, Deng J, Ai D, Liu Q, Wang S, Wu S, Chen J, Zhao K. Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics 2020;108:707-15. [DOI: 10.1016/j.ijrobp.2020.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
331 Vošmik M, Hodek M, Buka D, Sýkorová P, Grepl J, Paluska P, Paulíková S, Sirák I. Cardiotoxicity of radiation therapy in esophageal cancer. Rep Pract Oncol Radiother 2020;25:318-22. [PMID: 32194352 DOI: 10.1016/j.rpor.2020.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
332 Cong E, Oar AJ, Lee MT, Chicco A, Lin M, Yap J, Lin P, Ho Shon I. Novel 5-point 18-FDG-PET/CT visual scoring system for assessing treatment response in patients with oesophageal or gastro-oesophageal junction carcinoma. J Med Imaging Radiat Oncol 2021;65:23-37. [PMID: 33063470 DOI: 10.1111/1754-9485.13110] [Reference Citation Analysis]
333 Bose K, Franck C, Müller MN, Canbay A, Link A, Venerito M. Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions. Gastroenterol Res Pract 2017;2017:5651903. [PMID: 28785280 DOI: 10.1155/2017/5651903] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
334 Hajj A, Ghosn M, Mourad D, Hojaiban K, Mousallem P, Khabbaz LR. Lethal hepatotoxicity following 5-fluorouracil/cisplatin chemotherapy: a relevant case report. Per Med 2017;14:197-201. [PMID: 29767581 DOI: 10.2217/pme-2016-0085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
335 Ashrafi D, Memon B, Memon MA. Management of oesophageal intramucosal carcinoma. BMJ Case Rep 2018;2018:bcr-2018-224893. [PMID: 30217797 DOI: 10.1136/bcr-2018-224893] [Reference Citation Analysis]
336 Kroese TE, Tapias L, Olive JK, Trager LE, Morse CR. Routine intraoperative jejunostomy placement and minimally invasive oesophagectomy: an unnecessary step? Eur J Cardiothorac Surg. 2019;. [PMID: 30907417 DOI: 10.1093/ejcts/ezz063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
337 Davarzani N, Hutchins GGA, West NP, Hewitt LC, Nankivell M, Cunningham D, Allum WH, Smyth E, Valeri N, Langley RE, Grabsch HI. Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial. Histopathology 2018;72:1180-8. [PMID: 29465751 DOI: 10.1111/his.13491] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
338 Cartwright E, Cunningham D. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. Curr Treat Options Oncol 2017;18:69. [PMID: 29143893 DOI: 10.1007/s11864-017-0510-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
339 Hauge T, Amdal CD, Falk RS, Johannessen HO, Johnson E. Long-term outcome in patients operated with hybrid esophagectomy for esophageal cancer - a cohort study. Acta Oncol 2020;59:859-65. [PMID: 32324079 DOI: 10.1080/0284186X.2020.1750694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
340 Luijten JCHBM, Haagsman VC, Luyer MDP, Vissers PAJ, Nederend J, Huysentruyt C, Creemers GJ, Curvers W, van der Sangen M, Heesakkers FBM, Schrauwen RWM, Jürgens MC, Buster EHCJ, Vincent J, Kneppelhout JK, Verhoeven RHA, Nieuwenhuijzen GAP. Implementation of a regional video multidisciplinary team meeting is associated with an improved prognosis for patients with oesophageal cancer A mixed methods approach. Eur J Surg Oncol 2021:S0748-7983(21)00448-0. [PMID: 33926781 DOI: 10.1016/j.ejso.2021.04.020] [Reference Citation Analysis]
341 Lutz MP, Zalcberg JR, Ducreux M, Adenis A, Allum W, Aust D, Carneiro F, Grabsch HI, Laurent-Puig P, Lordick F, Möhler M, Mönig S, Obermannova R, Piessen G, Riddell A, Röcken C, Roviello F, Schneider PM, Seewald S, Smyth E, van Cutsem E, Verheij M, Wagner AD, Otto F. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur J Cancer 2019;112:1-8. [PMID: 30878666 DOI: 10.1016/j.ejca.2019.01.106] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
342 Mönig S, Chevallay M, Niclauss N, Zilli T, Fang W, Bansal A, Hoeppner J. Early esophageal cancer: the significance of surgery, endoscopy, and chemoradiation. Ann N Y Acad Sci 2018;1434:115-23. [PMID: 30138532 DOI: 10.1111/nyas.13955] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
343 Helminen O, Mrena J, Sihvo E. Can We Increase the Resection Rate by Minimally Invasive Approach? Experience from 100 Minimally Invasive Esophagectomies. J Oncol 2019;2019:3809383. [PMID: 30915119 DOI: 10.1155/2019/3809383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
344 Kawahara D, Murakami Y, Tani S, Nagata Y. A prediction model for degree of differentiation for resectable locally advanced esophageal squamous cell carcinoma based on CT images using radiomics and machine-learning. Br J Radiol 2021;94:20210525. [PMID: 34235955 DOI: 10.1259/bjr.20210525] [Reference Citation Analysis]
345 Depypere LP, Moons J, Lerut TE, Coosemans W, Van Veer H, Nafteux PR. Palliative esophagectomy in unexpected metastatic disease: sense or nonsense? Asian Cardiovasc Thorac Ann 2018;26:552-7. [PMID: 30185072 DOI: 10.1177/0218492318797228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
346 Kitajima K, Kaida H, Nakatani K, Ishibashi M, Morita T, Nakajo M, Tamaki Y, Minamimoto R. Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors: multicenter study in Japan. Nucl Med Commun 2020;41:443-51. [PMID: 32187159 DOI: 10.1097/MNM.0000000000001168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
347 Cavallin F, Scarpa M, Cagol M, Alfieri R, Ruol A, Chiarion Sileni V, Rugge M, Ancona E, Castoro C. Time to diagnosis in esophageal cancer: a cohort study. Acta Oncol 2018;57:1179-84. [PMID: 29600882 DOI: 10.1080/0284186X.2018.1457224] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
348 Barbour A, Walpole E, Mai G, Barnes E, Watson D, Ackland S, Martin J, Burge M, Finch R, Karapetis C, Shannon J, Nott L, Varma S, Marx G, Falk G, Gebski V, Oostendorp M, Wilson K, Thomas J, Lampe G, Zalcberg J, Simes J, Smithers B, Barbour A, Simes J, Walpole E, Mai T, Watson D, Karapetis C, Gebski V, Barnes L, Oostendorp M, Wilson K. Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial. Annals of Oncology 2020;31:236-45. [DOI: 10.1016/j.annonc.2019.10.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
349 Jeong DY, Lee KS, Choi JY, Chung MJ, Min YW, Kim HK, Zo JI, Shim YM, Sun JM. Surgically Resected Esophageal Squamous Cell Carcinoma: Patient Survival and Clinicopathological Prognostic Factors. Sci Rep 2020;10:5077. [PMID: 32193500 DOI: 10.1038/s41598-020-62028-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
350 Mallet R, Modzelewski R, Lequesne J, Mihailescu S, Decazes P, Auvray H, Benyoucef A, Di Fiore F, Vera P, Dubray B, Thureau S. Prognostic value of sarcopenia in patients treated by Radiochemotherapy for locally advanced oesophageal cancer. Radiat Oncol 2020;15:116. [PMID: 32443967 DOI: 10.1186/s13014-020-01545-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]